<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men - Sathianathen, NJ - 2021 | Cochrane Library</title> <meta content="Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men - Sathianathen, NJ - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012799.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men - Sathianathen, NJ - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012799.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012799.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men" name="citation_title"/> <meta content="Niranjan J Sathianathen" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="niranjan19@gmail.com" name="citation_author_email"/> <meta content="Eu Chang Hwang" name="citation_author"/> <meta content="Chonnam National University Medical School, Chonnam National University Hwasun Hospital" name="citation_author_institution"/> <meta content="Ruma Mian" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Joshua A Bodie" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Ayman Soubra" name="citation_author"/> <meta content="Jennifer A Lyon" name="citation_author"/> <meta content="Children's Mercy Hospital" name="citation_author_institution"/> <meta content="Shahnaz Sultan" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012799.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/03/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012799.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012799.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012799.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Coitus [psychology]; Confidence Intervals; Ejaculation [drug effects]; Odds Ratio; Patient Satisfaction [statistics &amp; numerical data]; Placebos [therapeutic use]; Premature Ejaculation [*drug therapy, psychology]; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012799.pub2&amp;doi=10.1002/14651858.CD012799.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012799\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012799\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","th","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012799.pub2",title:"Selective serotonin re\\u2010uptake inhibitors for premature ejaculation in adult men",firstPublishedDate:"Mar 21, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012799.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012799.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012799.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012799.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012799.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012799.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012799.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012799.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012799.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012799.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6486 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012799.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-sec-0147"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-sec-0022"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-sec-0023"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-sec-0065"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-sec-0141"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/appendices#CD012799-sec-0152"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/table_n/CD012799StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/table_n/CD012799StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#CD012799-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Niranjan J Sathianathen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#CD012799-cr-0005">Eu Chang Hwang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#CD012799-cr-0006">Ruma Mian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#CD012799-cr-0007">Joshua A Bodie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#CD012799-cr-0008">Ayman Soubra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#CD012799-cr-0009">Jennifer A Lyon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#CD012799-cr-0010">Shahnaz Sultan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information#CD012799-cr-0011">Philipp Dahm</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information/en#CD012799-sec-0165">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 March 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012799.pub2">https://doi.org/10.1002/14651858.CD012799.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012799-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012799-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012799-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012799-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012799-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012799-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012799-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012799-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012799-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012799-abs-0001" lang="en"> <section id="CD012799-sec-0001"> <h3 class="title" id="CD012799-sec-0001">Background</h3> <p>Premature ejaculation (PE) is a common problem among men that occurs when ejaculation happens sooner than a man or his partner would like during sex; it may cause unhappiness and relationship problems. Selective serotonin re‐uptake inhibitors (SSRIs), which are most commonly used as antidepressants are being used to treat this condition. </p> </section> <section id="CD012799-sec-0002"> <h3 class="title" id="CD012799-sec-0002">Objectives</h3> <p>To assess the effects of SSRIs in the treatment of PE in adult men.</p> </section> <section id="CD012799-sec-0003"> <h3 class="title" id="CD012799-sec-0003">Search methods</h3> <p>We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, CINAHL), clinical trial registries, conference proceedings, and other sources of grey literature, up to 1 May 2020. We applied no restrictions on publication language or status. </p> </section> <section id="CD012799-sec-0004"> <h3 class="title" id="CD012799-sec-0004">Selection criteria</h3> <p>We included only randomized controlled clinical trials (parallel group and cross‐over trials) in which men with PE  were administered SSRIs or placebo. We also considered 'no treatment' to be an eligible comparator but did not find any relevant studies. </p> </section> <section id="CD012799-sec-0005"> <h3 class="title" id="CD012799-sec-0005">Data collection and analysis</h3> <p>Two review authors independently classified and abstracted data from the included studies. Primary outcomes were participant‐perceived change with treatment, satisfaction with intercourse and study withdrawal due to adverse events. Secondary outcomes included self‐perceived control over ejaculation, participant distress about PE, adverse events and intravaginal ejaculatory latency time (IELT). We performed statistical analyses using a random‐effects model. We rated the certainty of evidence according to GRADE. </p> </section> <section id="CD012799-sec-0006"> <h3 class="title" id="CD012799-sec-0006">Main results</h3> <p>We identified 31 studies in which 8254 participants were randomized to receiving either SSRIs or placebo. </p> <p><b>Primary outcomes:</b> SSRI treatment probably improves self‐perceived PE symptoms (defined as a rating of 'better' or 'much better') compared to placebo (risk ratio (RR) 1.92, 95% confidence interval (CI) 1.66 to 2.23; moderate‐certainty evidence). Based on 220 participants per 1000 reporting improvement with placebo, this corresponds to 202 more men per 1000 (95% CI 145 more to 270 more) with improved symptoms with SSRIs.  </p> <p>SSRI treatment probably improves satisfaction with intercourse compared to placebo (defined as a rating of 'good' or 'very good'; RR 1.63, 95% CI 1.42 to 1.87; moderate‐certainty evidence). Based on 278 participants per 1000 reporting improved satisfaction with placebo, this corresponds to 175 more (117 more to 242 more) per 1000 men with greater satisfaction with intercourse with SSRIs. </p> <p>SSRI treatment may increase treatment cessations due to adverse events compared to placebo (RR 3.80, 95% CI 2.61 to 5.51; low‐certainty evidence). Based 11 study withdrawals per 1000 participants with placebo, this corresponds to 30 more men per 1000 (95% CI 17 more to 49 more) ceasing treatment due to adverse events with SSRIs.  </p> <p><b>Secondary outcomes:</b> SSRI treatment likely improve participants' self‐perceived control over ejaculation (defined as rating of 'good' or 'very good') compared to placebo (RR 2.29, 95% CI 1.72 to 3.05; moderate‐certainty evidence). Assuming 132 per 1000 participants perceived at least good control, this corresponds to 170 more (95 more to 270 more) reporting at least good control with SSRIs.  </p> <p>SSRI probably lessens distress (defined as rating of 'a little bit' or 'not at all') about PE (RR 1.54, 95% CI 1.26 to 1.88; moderate‐certainty evidence). Based on 353 per 1000 participants reporting low levels of distress, this corresponds to 191 more men (92 more to 311 more) per 1000 reporting low levels of distress with SSRIs.  </p> <p>SSRI treatment probably increases adverse events compared to placebo (RR 1.71, 95% CI 1.48 to 1.99; moderate‐certainty evidence). Based on 243 adverse events per 1000 among men receiving placebo, this corresponds to 173 more (117 more to 241 more) men having an adverse event with SSRIs.  </p> <p>SSRI treatment may increase IELT compared to placebo (mean difference (MD) 3.09 minutes longer, 95% CI 1.94 longer to 4.25 longer; low‐certainty evidence). </p> </section> <section id="CD012799-sec-0007"> <h3 class="title" id="CD012799-sec-0007">Authors' conclusions</h3> <p>SSRI treatment for PE appears to substantially improve a number of outcomes of direct patient importance such as symptom improvement, satisfaction with intercourse and perceived control over ejaculation when compared to placebo. Undesirable effects are a small increase in treatment withdrawals due to adverse events as well as substantially increased adverse event rates. Issues affecting the certainty of evidence of outcomes were study limitations and imprecision. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012799-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012799-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012799-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012799-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012799-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012799-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012799-abs-0011">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012799-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012799-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012799-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012799-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012799-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012799-abs-0002" lang="en"> <h3>Selective serotonin re‐uptake inhibitors for premature ejaculation</h3> <p><b>Review question</b> </p> <p>We wanted to find out if medicines called selective serotonin re‐uptake inhibitors (SSRIs), which are used mostly to treat depression, can help men that ejaculate faster than they want, to slow down. </p> <p><b>Background</b> </p> <p>Premature ejaculation is a common problem among men, that occurs when ejaculation happens sooner than a man or his partner would like during sex; it may cause unhappiness and relationship problems. SSRIs are medicines that are often given to help treat premature ejaculation, but we do not understand how well they actually work and what unwanted effects they might cause. </p> <p><b>Study characteristics</b> </p> <p>We studied the evidence up to 1 May 2020. We found 31 studies with 8254 men. The studies compared SSRIs to placebo (a pill with inactive ingredients). </p> <p><b>Key results</b> </p> <p>SSRIs probably improve sexual satisfaction for men with premature ejaculation compared to placebo. They probably also improve the sense of control over ejaculation and decrease unhappiness and relationship problems. However, they likely increase side effects. </p> <p><b>Quality of evidence</b> </p> <p>We judged the quality of evidence to be moderate for SSRIs, helping men’s sense of change with treatment, happiness with intercourse, and feeling of control over ejaculation. The quality of evidence was also moderate for medicine side effects. These results mean that our evaluation is likely to be close to the truth. However, the evidence on improving relationship problems and the time to ejaculation is of low certainty. This means that the true effect of treatment on those two concerns could be different from the results of this review. That may be caused by weaknesses and variations in the studies we examined. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012799-sec-0147" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012799-sec-0147"></div> <h3 class="title" id="CD012799-sec-0148">Implications for practice</h3> <section id="CD012799-sec-0148"> <p>Compared to placebo, the administration of selective serotonin re‐uptake inhibitors (SSRIs) for premature ejaculation (PE) may improve perception of change with treatment and satisfaction with intercourse. SSRIs may also improve perceived control over ejaculation and reduce both distress about PE and relationship difficulties. These potential benefits need to be weighed up against the possible increase in adverse events with SSRIs. Moreover, men should be counseled about the low certainty of evidence in this subject and, therefore, the possibility that the effects they experience from SSRI treatment for PE may be different to that shown in this review. </p> </section> <h3 class="title" id="CD012799-sec-0149">Implications for research</h3> <section id="CD012799-sec-0149"> <p>Considering the moderate‐ to low‐certainty evidence for the patient‐centered outcomes assessed in this review, future trials should be designed and conducted with higher methodologic standards so that we can have more certainty in the estimates. Future studies should also focus on patient‐important outcomes such as perception of change with treatment, satisfaction with intercourse, perceived control over ejaculation, participant distress about PE and relationship difficulties, which only a limited number of trials included in this review measured. Additionally, it is important that the effectiveness of SSRIs is compared to other active treatments directly to characterize the most efficacious management option. Currently, we are mostly relying on indirect evidence when trying to choose between the available pharmacologic agents (<a href="./references#CD012799-bbs2-0180" title="SridharanK , SivaramakrishnanG , SequeiraR , Al-KhajaKA . Pharmacological interventions for premature ejaculation: a mixed-treatment comparison network meta-analysis of randomized clinical trials. International Journal of Impotence Research2018;30(5):215-23.">Sridharan 2018</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012799-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012799-sec-0008"></div> <div class="table" id="CD012799-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">SSRI compared to placebo for premature ejaculation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SSRI compared to placebo for premature ejaculation in adult men</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult men with premature ejaculation<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> SSRI<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with SSRI</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant perception of change with treatment</b><br/>assessed with: Clinical Global Impression of Change questionnaire (event is good as it represents improvement in symptoms) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3260<br/>(6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.92</b><br/>(1.66 to 2.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in perceived improvement compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 more per 1000<br/>(145 more to 270 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant satisfaction with intercourse</b><br/>assessed with: Premature Ejaculation Profile questionnaire (event is good as it represents increased satisfaction) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4273<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.63</b><br/>(1.42 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in improved satisfaction with intercourse compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 more per 1000<br/>(117 more to 242 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study withdrawal due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>7367<br/>(20 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.80</b><br/>(2.61 to 5.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI may result in more withdrawals due to adverse events compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 more per 1000<br/>(17 more to 49 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Perceived control over ejaculation</b><br/>assessed with: Premature Ejaculation Profile questionnaire (event is good as it represents increased control over ejaculation) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4273<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.29</b><br/>(1.72 to 3.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in improved perceived control over ejaculation compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170 more per 1000<br/>(95 more to 270 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant distress about PE</b><br/>assessed with: Premature Ejaculation Profile questionnaire (event is good as it represents less distress) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>652<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.54</b><br/>(1.26 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in increased numbers of men not distressed about PE compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>353 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 more per 1000<br/>(92 more to 311 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4624<br/>(17 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.71</b><br/>(1.48 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in increased adverse events compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 more per 1000<br/>(117 more to 241 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IELT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5872<br/>(20 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean IELT was 1.41 minutes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.09 minutes</b> higher<br/>(1.94 higher to 4.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SSRI probably results in extended IELT compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IELT:</b> intravaginal ejaculatory latency time; <b>MD:</b> mean difference; <b>PE:</b> premature ejaculate; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SSRI:</b> selective serotonin reuptake inhibitor. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: most studies had an unclear or high risk of selection, performance and detection bias.<br/><sup>b</sup>Not downgraded for high I² statistic since observed inconsistency did not appear clinically relevant.<br/><sup>c</sup>Downgraded one level due to serious concerns regarding attrition bias.<br/><sup>d</sup>Downgraded one level for serious inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012799-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012799-sec-0009"></div> <section id="CD012799-sec-0010"> <h3 class="title" id="CD012799-sec-0010">Description of the condition</h3> <p>Premature ejaculation (PE) is broadly defined as a male sexual disorder in which ejaculation occurs at a time earlier than desired by the patient or his partner, or both, usually with minimal sexual stimulation before, or shortly after penetration. Other names for this condition are early ejaculation, rapid ejaculation, rapid climax, premature climax and (historically) ejaculatio praecox. The International Society of Sexual Medicine's guideline for PE provides a more specific definition: "a male sexual dysfunction characterized by ejaculation that always or nearly always occurs prior to or within one minute of vaginal penetration, either present from the first sexual experience or following a new bothersome change in ejaculatory latency, and the inability to delay ejaculation on all or nearly all vaginal penetrations, and negative personal consequences, such as distress, bother, frustration, and/or the avoidance of sexual intimacy" (<a href="./references#CD012799-bbs2-0174" title="SerefogluEC , McMahonCG , WaldingerMD , AlthofSE , ShindelA , AdaikanG , et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the Second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. Journal of Sexual Medicine2014;11(6):1423-41.">Serefoglu 2014</a>). It should be noted that other definitions of PE have been proposed but these have not been widely adopted or have not been evidence‐based (<a href="./references#CD012799-bbs2-0153" title="McMahonCG , AbdoC , IncrocciL , PerelmanM , RowlandD , WaldingerM , et al. Disorders of orgasm and ejaculation in men. Journal of Sexual Medicine2004;1(1):58-65.">McMahon 2004</a>). However, all these definitions were based around time to ejaculation, the inability to control ejaculation and the negative impact on an individual. </p> <p>There are several classification systems for subtypes of PE, but the commonly used Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM‐V) and International Classification of Diseases 11th Revision (ICD‐11) define four broad subtypes: lifelong, acquired, natural variable and premature‐like ejaculatory dysfunction (<a href="./references#CD012799-bbs2-0188" title="WaldingerMD , SchweitzerDH . Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II – proposals for DSM-V and ICD-11. Journal of Sexual Medicine2006;3(4):693-705.">Waldinger 2006</a>; <a href="./references#CD012799-bbs2-0189" title="WaldingerMD . Premature ejaculation: state of the art. Urologic Clinics of North America2007;34(4):591-9, vii-viii.">Waldinger 2007</a>). This classification likely encompasses most types of patients encountered in clinical practice. A clinical differentiation has been made between primary or lifelong versus secondary or acquired PE. With lifelong (primary) PE, the patient has experienced PE since the beginning of sexual life and it occurs in the absence of organic illnesses. Men with acquired PE encounter ejaculatory problems later in their lifetime after normal encounters in adolescence. There is generally a somatic or psychological dysfunction that is underpinning the ejaculatory problems, such as, urogenital disease, thyroid abnormalities or relationship problems. The treatment of acquired PE is based on addressing the underlying issue. </p> <p>PE has a significant negative impact on a man's quality of life. <a href="./references#CD012799-bbs2-0168" title="RowlandsDL , PatrickDL , RothamnM , GagnonDD . The psychological burden of premature ejaculation. Journal of Urology2007;177(3):1065-70.">Rowlands 2007</a> reported that men with PE have lower satisfaction with intercourse, increased personal distress and more interpersonal difficulty. These issues are also reflected in the female partners of men with PE. There are reports that the adverse effects of PE extend into a man's overall quality of life with lower 36‐item Short Form (SF‐36) scores in the following domains: general health, vitality, social function, emotional, mental health, role‐physical and the mental health component score (<a href="./references#CD012799-bbs2-0168" title="RowlandsDL , PatrickDL , RothamnM , GagnonDD . The psychological burden of premature ejaculation. Journal of Urology2007;177(3):1065-70.">Rowlands 2007</a>). Thus, successful treatment of PE has the potential to markedly improve quality of life. </p> <section id="CD012799-sec-0011"> <h4 class="title">Pathophysiology of premature ejaculation</h4> <p>The pathophysiology of PE is not completely understood. Ejaculation represents the last phase of the sexual response cycle. It is a reflex requiring interaction of somatic, sympathetic and parasympathetic nerve functions of mostly central dopaminergic and serotonergic neurons (<a href="./references#CD012799-bbs2-0121" title="BuvatJ . Pathophysiology of premature ejaculation. Journal of Sexual Medicine2011;8 Suppl 4:316-27.">Buvat 2011</a>; <a href="./references#CD012799-bbs2-0153" title="McMahonCG , AbdoC , IncrocciL , PerelmanM , RowlandD , WaldingerM , et al. Disorders of orgasm and ejaculation in men. Journal of Sexual Medicine2004;1(1):58-65.">McMahon 2004</a>). The somatic system with the pudendal nerve enables the expulsion phase of ejaculation. Based on experimental studies in animals, serotonin has an important regulatory role in ejaculation. Different types of serotonin receptors exist in the brain, spine and peripheral autonomic ganglia, where they either have a stimulatory or inhibitory effect on ejaculation (<a href="./references#CD012799-bbs2-0184" title="WaldingerMD . The neurobiological approach to premature ejaculation. Journal of Urology2002;168(6):2359-67.">Waldinger 2002</a>). One of the underlying issues in PE appears to be a diminished sensitivity of one type of receptor versus the increased sensitivity of another type of receptor to serotonin. The exact cause of this problem remains unclear. Genetic, neurobiologic, pharmacologic, psychological, urologic and endocrine factors have been implicated (<a href="./references#CD012799-bbs2-0121" title="BuvatJ . Pathophysiology of premature ejaculation. Journal of Sexual Medicine2011;8 Suppl 4:316-27.">Buvat 2011</a>). Genetic factors include variations in the serotonin‐transporter‐linked promoter region (5‐HTTLPR) on chromosome 17 where the short allele has been shown to be more prevalent in men with PE compared to controls (<a href="./references#CD012799-bbs2-0157" title="OzbekE , TasciAI , TugcuV , IlbeyYO , SimsekA , OzcanL , et al. Possible association of the 5-HTTLPR serotonin transporter promoter gene polymorphism with premature ejaculation in a Turkish population. Asian Journal of Andrology2009;11(3):351-5.">Ozbek 2011</a>). It is likely that PE is multifactorial and that psychological and somatic factors and psychological stress contribute (<a href="./references#CD012799-bbs2-0121" title="BuvatJ . Pathophysiology of premature ejaculation. Journal of Sexual Medicine2011;8 Suppl 4:316-27.">Buvat 2011</a>). Developmental factors such as history of sexual abuse, negative attitudes towards sex or individual psychological factors such as a negative body image, depression and performance anxiety may also play a role at times (<a href="./references#CD012799-bbs2-0118" title="AlthofSE , McMahonCG , WaldingerMD , SerefogluEC , ShindelAW , AdaikanPG , et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). Journal of Sexual Medicine2014;11(6):1392-422. [DOI: 10.1111/jsm.12504]">Althof 2014</a>). </p> </section> <section id="CD012799-sec-0012"> <h4 class="title">Epidemiology</h4> <p>There have been largely variable estimates of PE prevalence because of the contention in the exact definition. Historical data from The USA National Health and Social Life Survey estimated that nearly one‐third of all adult males under 60 years of age in 1992 had PE (<a href="./references#CD012799-bbs2-0148" title="LaumannEO , PaikA , RosenRC . Sexual dysfunction in the United States: prevalence and predictors. JAMA1999;281(6):537-44.">Laumann 1999</a>). However, it is thought this is a gross overestimate given the number of men that present for medical attention. Contemporary data estimates the prevalence of lifelong and acquired PE as 5% of the general population (<a href="./references#CD012799-bbs2-0118" title="AlthofSE , McMahonCG , WaldingerMD , SerefogluEC , ShindelAW , AdaikanPG , et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). Journal of Sexual Medicine2014;11(6):1392-422. [DOI: 10.1111/jsm.12504]">Althof 2014</a>). </p> </section> <section id="CD012799-sec-0013"> <h4 class="title">Diagnosis</h4> <p>Diagnosis of PE is predominantly based on the medical and sexual history of the man (<a href="./references#CD012799-bbs2-0175" title="ShabsighR . Diagnosing premature ejaculation: a review. Journal of Sexual Medicine2006;3(Suppl 4):318-23.">Shabsigh 2006</a>). Specifically, clinicians should ask patients how long they have had PE; how often it occurs; whether it happens during all sexual encounters and with all partners; whether the degree of sexual stimulation matters and how often they engage in sexual activity including masturbation, foreplay and intercourse. Clinicians should also ask the patient to estimate their intravaginal ejaculatory latency time (IELT), ideally with corroboration of this information by a partner if present. While assessing IELT with a stopwatch is widely used in clinical trials, it is not routinely used in clinical practice due to the intrusive nature of this measurement method and because it has been shown to be relatively comparable to self‐estimated IELT (<a href="./references#CD012799-bbs2-0118" title="AlthofSE , McMahonCG , WaldingerMD , SerefogluEC , ShindelAW , AdaikanPG , et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). Journal of Sexual Medicine2014;11(6):1392-422. [DOI: 10.1111/jsm.12504]">Althof 2014</a>; <a href="./references#CD012799-bbs2-0166" title="RosenRC , McMahonCG , NiederbergerC , BroderickGA , JamiesonC , GagnonDD . Correlates to the clinical diagnosis of premature ejaculation: results from a large observational study of men and their partners. Journal of Urology2007;177(3):1059-64.">Rosen 2007a</a>). </p> <p>It is also helpful to ask the patient to define his perceived control over ejaculation, the perceived degree of bother related to PE and the impact it has on his relationship(s). <a href="./references#CD012799-bbs2-0144" title="KempeneersP , AndrianneR , BauwensS , GeorisI , PairouxJF , BlairyS . Functional and psychological characteristics of Belgian men with premature ejaculation and their partners. Archives of Sexual Behavior2013;42(1):51-66.">Kempeneers 2013</a> reported that sexual satisfaction and distress better reflected the feeling of control than self‐estimated IELT. There are several questionnaires that have been developed to diagnose PE and characterize its effect on quality of life. These include the Premature Ejaculation Diagnostic Tool (PEDT) (<a href="./references#CD012799-bbs2-0183" title="SymondsT , PerelmanMA , AlthofS , GiulianoF , MartinM , MayK , et al. Development and validation of a premature ejaculation diagnostic tool. European Urology2007;52(2):565-73.">Symonds 2007</a>), Arabic Index of Premature Ejaculation (<a href="./references#CD012799-bbs2-0120" title="ArafaM , ShamloulR . Development and evaluation of the Arabic Index of Premature Ejaculation (AIPE). Journal of Sexual Medicine2007;4(6):1750-6.">Arafa 2007</a>), Premature Ejaculation Profile (PEP) (<a href="./references#CD012799-bbs2-0158" title="PatrickDL , GiulianoF , HoKF , GagnonDD , McNultyP , RothmanM . The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice. BJU International2009;103(3):358-64.">Patrick 2009</a>), and Male Sexual Health Questionnaire Ejaculatory Dysfunction (<a href="./references#CD012799-bbs2-0167" title="RosenRC , CataniaJA , AlthofSE , PollackLM , O'LearyM , SeftelAD , et al. Development and validation of four-item version of male sexual health questionnaire to assess ejaculatory dysfunction. Urology2007;69(5):805-9.">Rosen 2007b</a>). </p> <p>It is important to distinguish between PE and erectile dysfunction (ED), recognizing that some men with ED may develop secondary PE. Vice versa, men with lifelong PE may develop ED as they age. Furthermore, possible acquired (secondary) causes of PE should be explored in an attempt to define the relevant subtype. Although physical examination is an essential part of the patient evaluation, it is unusual to find anything that explains the etiology of the patient's PE (<a href="./references#CD012799-bbs2-0175" title="ShabsighR . Diagnosing premature ejaculation: a review. Journal of Sexual Medicine2006;3(Suppl 4):318-23.">Shabsigh 2006</a>). </p> </section> <section id="CD012799-sec-0014"> <h4 class="title">Treatment</h4> <p>Treatment approaches to PE, other than selective serotonin re‐uptake inhibitors (SSRIs), can be broadly categorized into behavioral therapy, oral agents and topical agents (<a href="./references#CD012799-bbs2-0118" title="AlthofSE , McMahonCG , WaldingerMD , SerefogluEC , ShindelAW , AdaikanPG , et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). Journal of Sexual Medicine2014;11(6):1392-422. [DOI: 10.1111/jsm.12504]">Althof 2014</a>; <a href="./references#CD012799-bbs2-0123" title="CastiglioneF , AlbersenM , HedlundP , GratzkeC , SaloniaA , GiulianoF . Current pharmacological management of premature ejaculation: a systematic review and meta-analysis. European Urology2016;69(5):904-16.">Castiglione 2016</a>). We have introduced the most widely used treatment options below. </p> <section id="CD012799-sec-0015"> <h5 class="title">Behavioral therapy</h5> <p>Behavioral psychosexual therapies predate the use of pharmacologic agents by decades (<a href="./references#CD012799-bbs2-0126" title="CooperK , Martyn-St JamesM , KaltenthalerE , DickinsonK , CantrellA . Interventions to treat premature ejaculation: a systematic review short report. Health Technology Assessment2015;19(21):1-180, v-vi.">Cooper 2015</a>). </p> <p> <ul id="CD012799-list-0001"> <li> <p>One early approach was referred to as the 'stop‐start' technique (<a href="./references#CD012799-bbs2-0173" title="SemansJH . Premature ejaculation: a new approach. Southern Medical Journal1956;49(4):353-8.">Semans 1956</a>). It involves partner stimulation of the man's penis until the sensation of near climaxing at which time stimulation is abruptly stopped until the sensation of imminent orgasm disappears. This exercise is repeated until the patient learns to voluntarily control his ejaculations. </p> </li> <li> <p>Masters and Johnson reported a similar maneuver in which the partner squeezes the penis and stops penile stimulation (<a href="./references#CD012799-bbs2-0155" title="MelnikT , AlthofS , AtallahAN , PugaME , GlinaS , RieraR . Psychosocial interventions for premature ejaculation. Cochrane Database of Systematic Reviews2011, Issue 8. Art. No: CD008195. [DOI: 10.1002/14651858.CD008195.pub2]">Melnik 2011</a>). After a short interval, the female partner restarts the stimulation. This is referred to as the 'squeeze' technique. </p> </li> </ul> </p> <p>The common feature of both approaches is distraction and the reduction of sexual excitement. It is intended to help men recognize the early signs for ejaculation/orgasm and work with their partner in improving self‐control. </p> </section> <section id="CD012799-sec-0016"> <h5 class="title">Oral agents</h5> <p> <ul id="CD012799-list-0002"> <li> <p>Clomipramine: a tricyclic antidepressant that inhibits the uptake of norepinephrine and serotonin. Findings of several randomized controlled trials (RCTs) summarized in systematic reviews and meta‐analyses indicate that the daily use of clomipramine increases IELT (<a href="./references#CD012799-bbs2-0125" title="ChoiJB , KangSH , LeeDH , KimYS , JeonJS , ChoiWS , et al. Efficacy and safety of on demand clomipramine for the treatment of premature ejaculation: a multicenter, randomized, double-blind, phase III clinical trial. Journal of Urology2019;201(1):147-52.">Choi 2019</a>; <a href="./references#CD012799-bbs2-0126" title="CooperK , Martyn-St JamesM , KaltenthalerE , DickinsonK , CantrellA . Interventions to treat premature ejaculation: a systematic review short report. Health Technology Assessment2015;19(21):1-180, v-vi.">Cooper 2015</a>; <a href="./references#CD012799-bbs2-0146" title="KimSW , ChoiJB , KimSJ , KimKS , KimCM , LeeDH . Tolerability and adequate therapeutic dosage of oral clomipramine for the treatment of premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose, parallel-grouped clinical study. International Journal of Impotence Research2018;30(2):65-70.">Kim 2018</a>; <a href="./references#CD012799-bbs2-0154" title="McMahonCG , PorstH . Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation. Journal of Sexual Medicine2011;8(10):2707-25.">McMahon 2011</a>). </p> </li> <li> <p>Tramadol: a synthetic opiate analgesic that is primarily used for pain control. Its mechanism of action in PE is not fully understood. Several RCTs and reviews suggest that it results in an increase in IELT (<a href="./references#CD012799-bbs2-0147" title="KirbyEW , CarsonCC , CowardRM . Tramadol for the management of premature ejaculation: a timely systematic review. International Journal of Impotence Research2015;27(4):121-7.">Kirby 2015</a>; <a href="./references#CD012799-bbs2-0150" title="Martyn-St JamesM , CooperK , KaltenthalerE , DickinsonK , CantrellA , WylieK , et al. Tramadol for premature ejaculation: a systematic review and meta-analysis. BMC Urology2015;15:6.">Martyn‐St James 2015</a>; <a href="./references#CD012799-bbs2-0170" title="SafarinejadMR , HosseiniSY . Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2006;26(1):27-31.">Safarinejad 2006a</a>; <a href="./references#CD012799-bbs2-0171" title="SalemEA , WilsonSK , BissadaNK , DelkJR , HellstromWJ , ClevesMA . Tramadol HCl has promise in on-demand use to treat premature ejaculation. Journal of Sexual Medicine2008;5(1):188-93.">Salem 2008</a>). </p> </li> <li> <p>Phosphodiesterase‐5 inhibitors: the primary role of this therapy is in treating ED. However, ED is also common among men with PE and there appears to be a benefit with sildenafil or tadalafil treatment (<a href="./references#CD012799-bbs2-0129" title="El-HamdMA . Efficacy and safety of daily use of tadalafil in treatment of patients with premature ejaculation: a randomised placebo-controlled clinical trial. Andrologia2018;50(5):e13005.">El‐Hamd 2018</a>; <a href="./references#CD012799-bbs2-0152" title="Martyn-St JamesM , CooperK , RenS , KaltenthalerE , Dickinson, CantrellA . Phosphodiesterase type 5 inhibitors for premature ejaculation: a systematic review and meta-analysis. European Urology Focus2017;3(1):119-29.">Martyn‐St James 2017</a>) </p> </li> <li> <p>Alfa‐adrenoreceptor antagonists: this drug class is primarily used to treat lower urinary tract symptoms associated with benign prostatic hyperplasia, but there are studies that have shown that it can improve PE (<a href="./references#CD012799-bbs2-0124" title="CavalliniG . Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. European Urology1995;28(2):126-30.">Cavallini 1995</a>). </p> </li> </ul> </p> </section> <section id="CD012799-sec-0017"> <h5 class="title">Topical agents</h5> <p>Topical agents decrease the sensitivity of the penis to sexual stimulation. Perceived advantages of these agents are the absence of systemic adverse effects. </p> <p> <ul id="CD012799-list-0003"> <li> <p>Lidocaine‐prilocaine (marketed as EMLA) is a local anesthetic cream for topical use that can anesthetize intact skin. Several trials indicate an increase in IELT (<a href="./references#CD012799-bbs2-0151" title="Martyn-St JamesM , CooperK , RenK , KaltenthalerE , DickinsonK , CantrellA , et al. Topical anaesthetics for premature ejaculation: a systematic review and meta-analysis. Sexual Health2016;13(1):114-23.">Martyn‐St James 2016</a>; <a href="./references#CD012799-bbs2-0160" title="PuC , YangL , LiuL , YuanH , WeiQ , HanP . Topical anesthetic agents for premature ejaculation: a systematic review and meta-analysis. Urology2013;81(4):799-804.">Pu 2013</a>; <a href="./references#CD012799-bbs2-0192" title="XiaJD , HanYF , ZhouLH , ChenY , DaiYT . Efficacy and safety of local anaesthetics for premature ejaculation: a systematic review and meta-analysis. Asian Journal of Andrology2013;15(4):497-502.">Xia 2013</a>). Adverse effects include some loss of penile sensitivity, ED and female genital anesthesia. </p> </li> </ul> </p> </section> </section> </section> <section id="CD012799-sec-0018"> <h3 class="title" id="CD012799-sec-0018">Description of the intervention</h3> <p>SSRIs are oral drugs primarily used to treat depression. Their effect on delaying ejaculation was first identified as an adverse effect in this setting (<a href="./references#CD012799-bbs2-0118" title="AlthofSE , McMahonCG , WaldingerMD , SerefogluEC , ShindelAW , AdaikanPG , et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). Journal of Sexual Medicine2014;11(6):1392-422. [DOI: 10.1111/jsm.12504]">Althof 2014</a>; <a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>). Depending on the type of agent and its half‐life, these drugs are used either daily or on‐demand. </p> <section id="CD012799-sec-0019"> <h4 class="title">Adverse effects of the intervention</h4> <p>The adverse effects of SSRIs are fairly well understood through their widespread and long‐term use in people with depression. </p> <p> <ul id="CD012799-list-0004"> <li> <p>The most common short‐term adverse effects are reported to be drowsiness, weight gain, dry mouth, insomnia, fatigue and nausea (<a href="./references#CD012799-bbs2-0122" title="CascadeE , KalaliAH , KennedySH . Real-world data on SSRI antidepressant side effects. Psychiatry2009;6(2):16-8.">Cascade 2009</a>). </p> </li> <li> <p>Sexual adverse effects such as reduced libido and new‐onset or worsening ED have been reported (<a href="./references#CD012799-bbs2-0122" title="CascadeE , KalaliAH , KennedySH . Real-world data on SSRI antidepressant side effects. Psychiatry2009;6(2):16-8.">Cascade 2009</a>). </p> </li> <li> <p>Stopping long‐term treatment of SSRIs may lead to 'SSRI discontinuation syndrome,' beginning one to three days after drug cessation and possibly continuing for more than one week. Symptoms include nausea, vomiting, dizziness, headache, ataxia, drowsiness, anxiety and insomnia. Therefore, it is recommended that SSRIs be gradually withdrawn over several weeks (<a href="./references#CD012799-bbs2-0156" title="MulhallJP . Premature ejaculation. In: WeinAJ , KavoussiLR , NovickA , PartinAW , PetersCA , editors(s). Campbell-Walsh Urology. 1st edition. Philadelphia: Elsevier Saunders, 2012:770-9.">Mulhall 2012</a>). </p> </li> <li> <p>Multiple drug interactions exist and can potentially lead to 'serotonin syndrome,' a group of serious, persistent symptoms including myoclonus, hyper‐reflexia, sweating, shivering, and motor co‐ordination and mental status changes (<a href="./references#CD012799-bbs2-0142" title="IqbalMM , BasilMJ , KaplanJ , IqbalMT . Overview of serotonin syndrome. Annals of Clinical Psychiatry2012;24(4):310-18.">Iqbal 2012</a>). </p> </li> <li> <p>Studies of depressed people treated with SSRIs have indicated a small increase in the risk of suicide ideation or suicide attempts, especially in younger age groups, but the evidence remains weak (<a href="./references#CD012799-bbs2-0159" title="PompiliM , SerafiniG , InnamoratiM , AmbrosiE , GiordanoG , GirardiP , et al. Antidepressants and suicide risk: a comprehensive overview. Pharmaceuticals2010;3(9):2861-83.">Pompili 2010</a>). Nonetheless, caution is urged in younger people with PE and concomitant depression or suicidal ideation, or both. Based on current guidelines, patients should also be advised to avoid sudden cessation or rapid dose reduction of daily dose SSRIs. </p> </li> </ul> </p> </section> </section> <section id="CD012799-sec-0020"> <h3 class="title" id="CD012799-sec-0020">How the intervention might work</h3> <p>The role of 5‐hydroxytryptamine (5‐HT) (also known as serotonin) in the process of ejaculation appears to be inhibitory. SSRIs work by the blockage of serotonin transporters at the level of the synapse resulting in increased concentrations (<a href="./references#CD012799-bbs2-0131" title="FullerRW . Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sciences1994;55(3):163-7.">Fuller 1994</a>; <a href="./references#CD012799-bbs2-0132" title="GiulianoF , ClementP . Serotonin and premature ejaculation: from physiology to patient management. European Urology2006;50(3):454-66.">Giuliano 2006</a>; <a href="./references#CD012799-bbs2-0186" title="WaldingerMD , SchweitzerDH , OlivierB . On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. Journal of Sexual Medicine2005;2(1):121-31.">Waldinger 2005a</a>). Based on a study of monkeys, administration of sertraline 20 mg/kg (an SSRI) resulted in the serotonin concentration in cerebrospinal fluid increasing by nearly 300% within hours of administration (<a href="./references#CD012799-bbs2-0119" title="AndersonGM , BarrCS , LindellS , DurhamAC , ShifrovichI , HigleyJD . Time course of the effects of the serotonin-selective reuptake inhibitor sertraline on central and peripheral serotonin neurochemistry in the Rhesus monkey. Psychopharmacology2005;178(2-3):339-46.">Anderson 2005</a>). Due to increased serotonin levels in the synapse, 5‐HT1A and 5‐HT1B receptors on the postsynaptic and presynaptic membranes become activated, causing a reduction in secretion of serotonin into the synapse (<a href="./references#CD012799-bbs2-0186" title="WaldingerMD , SchweitzerDH , OlivierB . On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. Journal of Sexual Medicine2005;2(1):121-31.">Waldinger 2005a</a>). These receptors ultimately become desensitized, resulting in the serotonin release into the synapse, but this time because of transport inhibition by the SSRI, the synaptic serotonin levels remain high, causing persistent activation of postsynaptic receptors, which is thought to mediate the clinical effects of SSRI including the prolongation of IELT (<a href="./references#CD012799-bbs2-0179" title="SprouseJ , BraseltonJ , ReynoldsL , ClarkeT , RollemaH . Activation of postsynaptic 5-HT(1A) receptors by fluoxetine despite the loss of firing-dependent serotonergic input: electrophysiological and neurochemical studies. Synapse2001;41(1):49-57.">Sprouse 2001</a>). </p> </section> <section id="CD012799-sec-0021"> <h3 class="title" id="CD012799-sec-0021">Why it is important to do this review</h3> <p>SSRIs are among the most widely used drugs for PE (<a href="./references#CD012799-bbs2-0118" title="AlthofSE , McMahonCG , WaldingerMD , SerefogluEC , ShindelAW , AdaikanPG , et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). Journal of Sexual Medicine2014;11(6):1392-422. [DOI: 10.1111/jsm.12504]">Althof 2014</a>), but others have also argued that PE is not a disease at all (<a href="./references#CD012799-bbs2-0161" title="PuppoV . Premature ejaculation during vaginal intercourse is not a male sexual dysfunction. Internal Medicine Journal2014;44(10):1049.">Puppo 2014</a>), or have raised the notion that the fairly recent availability of pharmacologic treatment of PE, including SSRIs, has reinforced stereotypes of 'normal' sexual conduct and thereby reinforced social norms that cause men distress (<a href="./references#CD012799-bbs2-0178" title="SoderfeldtY , DroppeA , OhnhauserT . Distress, disease, desire: perspectives on the medicalisation of premature ejaculation. Journal of Medical Ethics2017;1:1-2.">Soderfeldt 2017</a>). While most use of these agents is off‐label, dapoxetine, a short‐acting SSRI, is also approved for the treatment of PE in many countries outside the USA. Therefore, it is important for clinicians to fully understand both the benefits and potential harms associated with these agents as <a href="./references#CD012799-bbs2-0130" title="FeysF , DevroeyD . Dapoxetine for Premature Ejaculation: a Harmful Placebo? [PhD thesis]. Brussels: Brussels University Press, 2014. [DOI: 10.13140/2.1.3428.4169]">Feys 2014</a> raised the concern that dapoxetine may be a costly and dangerous placebo. Although multiple systematic reviews have been conducted on the treatment of PE, including the use of SSRIs (<a href="./references#CD012799-bbs2-0123" title="CastiglioneF , AlbersenM , HedlundP , GratzkeC , SaloniaA , GiulianoF . Current pharmacological management of premature ejaculation: a systematic review and meta-analysis. European Urology2016;69(5):904-16.">Castiglione 2016</a>; <a href="./references#CD012799-bbs2-0126" title="CooperK , Martyn-St JamesM , KaltenthalerE , DickinsonK , CantrellA . Interventions to treat premature ejaculation: a systematic review short report. Health Technology Assessment2015;19(21):1-180, v-vi.">Cooper 2015</a>; <a href="./references#CD012799-bbs2-0130" title="FeysF , DevroeyD . Dapoxetine for Premature Ejaculation: a Harmful Placebo? [PhD thesis]. Brussels: Brussels University Press, 2014. [DOI: 10.13140/2.1.3428.4169]">Feys 2014</a>; <a href="./references#CD012799-bbs2-0169" title="RussoA , CapogrossoP , VentimigliaE , La CroceG , BoeriL , MontorsiF , et al. Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review. International Journal of Clinical Practice2016;70(9):723-33.">Russo 2016</a>; <a href="./references#CD012799-bbs2-0185" title="WaldingerMD , ZwindermanAH , SchweitzerDH , OlivierB . Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. International Journal of Impotence Research2004;16(4):369-81.">Waldinger 2004</a>; <a href="./references#CD012799-bbs2-0193" title="YueFG , DongL , HuTT , QuXY . Efficacy of dapoxetine for the treatment of premature ejaculation: a meta-analysis of randomized clinical trials on intravaginal ejaculatory latency time, patient-reported outcomes, and adverse events. Urology2015;85(4):856-61.">Yue 2015</a>), these have not been performed in a methodologically rigorous manner. This review distinguishes itself by virtue of a published, a priori protocol governing all aspects of this study (New Reference), a comprehensive search of the literature not limited by publication status or language and its focus on patient‐important outcomes with rating of the certainty of evidence using the GRADE approach on a per‐outcome basis. Cochrane Reviews such as ours are also governed by a strict conflict of interest policy. Therefore, we expect this review to provide important, evidence‐based information for patients, clinicians, guideline developers and health policy makers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012799-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012799-sec-0022"></div> <p>To assess the effects of SSRIs in the treatment of PE in adult men.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012799-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012799-sec-0023"></div> <section id="CD012799-sec-0024"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012799-sec-0025"> <h4 class="title">Types of studies</h4> <p>We included RCTs in which participants were allocated to receive either SSRI or placebo/no treatment. We also included cross‐over clinical trials because we believed that this would be a suitable design to test interventions in PE as this is a relatively stable condition and SSRIs have a short half‐life (<a href="./references#CD012799-bbs2-0128" title="ElbourneDR ,  Altman DG, HigginsJP , Curtin F, WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). We did not consider cluster‐RCTs as they did not appear applicable to this particular clinical question.  </p> </section> <section id="CD012799-sec-0026"> <h4 class="title">Types of participants</h4> <p>We included studies of men aged ≥ 18 years with lifelong PE only (from first sexual experience). We excluded men with PE secondary to other known conditions such as prostatitis or PE as a medication side effect (acquired PE). </p> <section id="CD012799-sec-0027"> <h5 class="title">Diagnostic criteria for premature ejaculation</h5> <p>Since a standardized definition was developed by the International Society of Sexual Medicine in 2014 (see <a href="#CD012799-sec-0010">Description of the condition</a>), we included studies whether they used this definition or not (but recorded all definitions used). </p> </section> </section> <section id="CD012799-sec-0028"> <h4 class="title">Types of interventions</h4> <p>We investigated the following comparisons of intervention versus control/comparator.</p> <section id="CD012799-sec-0029"> <h5 class="title">Intervention</h5> <p> <ul id="CD012799-list-0005"> <li> <p>SSRI.</p> </li> </ul> </p> </section> <section id="CD012799-sec-0030"> <h5 class="title">Comparator</h5> <p> <ul id="CD012799-list-0006"> <li> <p>Placebo.</p> </li> <li> <p>No treatment (but we found no trials with no treatment as the comparator).</p> </li> </ul> </p> <p>Concomitant interventions were the same in both the intervention and comparator groups to establish fair comparisons. </p> <p>For trials with multiple arms, we included any arm that met the inclusion criteria in the review and listed all arms in the <a href="./references#CD012799-sec-0172" title="">Characteristics of included studies</a> table). </p> <p>We did not consider agents classified as serotonin‐norepinephrine re‐uptake inhibitors such as duloxetine. </p> </section> <section id="CD012799-sec-0031"> <h5 class="title">Minimum duration of intervention and follow‐up</h5> <p> <ul id="CD012799-list-0007"> <li> <p>Four weeks.</p> </li> </ul> </p> <p>We defined the trial duration according to the number of weeks over which the interventions and comparators were conducted and only included trials in the analyses with treatments that lasted at least four weeks. </p> </section> <section id="CD012799-sec-0032"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD012799-list-0008"> <li> <p>Males aged less than 18 years.</p> </li> <li> <p>Men with known conditions thought to cause PE or in whom PE was thought to be secondary to other medications. </p> </li> </ul> </p> </section> </section> <section id="CD012799-sec-0033"> <h4 class="title">Types of outcome measures</h4> <p>We did not exclude trials because one or several of our primary or secondary outcome measures were not reported in the publication. In case none of our primary or secondary outcomes were reported, we were unable to include such trials in the analysis but provided information for these trials in <a href="#CD012799-tbl-0002">Table 1</a> and <a href="#CD012799-tbl-0003">Table 2</a>. </p> <div class="table" id="CD012799-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of the interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) (route, frequency, total dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator(s) (route, frequency, total dose/day)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily for first 1 week and 40 mg daily for remaining 5 weeks after breakfast </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: duloxetine 20 mg daily for 1 week followed by 40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: citalopram 20 mg daily up to 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily up to 3 tablets</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg on‐demand</p> <p>I2: dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> <p>C2: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: citalopram 20 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo on‐demand</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg on‐demand + lubricating jelly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo on‐demand + lubricating jelly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tramadol 50 mg</p> <p>I2: paroxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg</p> <p>I2: paroxetine 20 mg 2–3 hours before intercourse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 40 mg daily for 1 week then 80 mg for 3 weeks</p> <p>I2: sertraline 100 mg for 1 week then 200 mg for 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> <p>C2: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 90 mg daily</p> <p>I2: fluoxetine 90 mg daily + tadalafil 20 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> <p>C2: placebo + tadalafil 20 mg on‐demand</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg</p> <p>I2: paroxetine as needed 3–4 hours before planned sexual intercourse</p> <p>I3: paroxetine 10 mg for 3 weeks then 20 mg paroxetine as needed for 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily for 3 weeks then placebo daily for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg daily</p> <p>I2: dapoxetine 60 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> <p>C2: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg on‐demand, from week 4 up to 60 mg if tolerated + PDE5 inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo on‐demand + PDE5 inhibitor</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg daily that could be titrated up to 200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg at night that could be titrated up to 100 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg on‐demand</p> <p>I2: dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo on‐demand 1–3 hours before anticipated sexual activity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 60 mg daily</p> <p>I2: paroxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: citalopram 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: escitalopram 10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: citalopram 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg nightly for 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily for 2 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg daily for 1 week and then 40 mg daily from week 2–6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily</p> <p>I2: fluvoxamine 100 mg daily</p> <p>I3: paroxetine 20 mg daily</p> <p>I4: sertraline 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>C: comparator; I: intervention; PDE5: phosphodiesterase‐5.</p> </div> </div> <div class="table" id="CD012799-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Age in years (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Baseline IELT in minutes (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants with primary/secondary PE</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: fluoxetine 20 mg daily for first 1 week and 40 mg daily for remaining 5 weeks after breakfast </p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.8 (range 34–48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (range 0.17–2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.8 (range 34–48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (range 0.17–2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: duloxetine 20 mg daily for 1 week followed by 40 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.35 (SD 8.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (SD 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.65 (SD 7.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (SD 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: citalopram 20 mg daily up to 60 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 24–46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 (SD 0.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 24–46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (SD 0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1995–1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (SD 0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (SD 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: dapoxetine 30 mg on‐demand</p> <p>I2: dapoxetine 60 mg on‐demand</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2004–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.6 (SD 9.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (SD 0.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.5 (SD 9.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (SD 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.1 (SD 9.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (SD 0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: citalopram 20 mg on‐demand</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.28 (SD 6.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (SD 0.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.76 (SD 5.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (SD 0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg on‐demand + lubricating jelly</p> <p>C1: placebo on‐demand + lubricating jelly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (SD 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: paroxetine 20 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>likely outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.8 (SD 5.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (SD 0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2 (SD 6.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (SD 0.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: tramadol 50 mg</p> <p>I2: paroxetine 20 mg</p> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: fluoxetine 20 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 15–50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (SD 0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 15–50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (SD 0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: dapoxetine 60 mg on‐demand</p> <p>C1: placebo on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.8 (SD 9.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.98 (SD 9.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: paroxetine 20 mg</p> <p>I2: paroxetine 20 mg 2–3 hours before intercourse</p> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Georgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.7 (range 19–39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.7 (range 19–39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.7 (range 19–39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: fluoxetine 40 mg daily for 1 week then 80 mg for 3 weeks</p> <p>I2: sertraline 100 mg for 1 week then 200 mg for 3 weeks</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (range 30–60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (SD 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (range 30–60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (SD 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (range 30–60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (SD 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>I1: fluoxetine 90 mg daily</p> <p>I2: fluoxetine 90 mg daily + tadalafil 20 mg on‐demand</p> <p>C1: placebo daily</p> <p>C2: placebo + tadalafil 20 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (SD 8.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (SD 0.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.81 (SD 7.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (SD 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.93 (SD 9.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (SD 0.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2 (SD 11.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (SD 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (range 19–70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (range 19–70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study 1: </b> </p> <p>I1: paroxetine 20 mg</p> <p>C1: paroxetine as needed 3–4 hours before planned sexual intercourse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study 2: </b> </p> <p>I2: paroxetine 10 mg for 3 weeks then 20 mg paroxetine as needed for 4 weeks</p> <p>C2: placebo daily for 3 weeks then placebo daily for 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: dapoxetine 30 mg on‐demand</p> <p>I2: dapoxetine 60 mg on‐demand</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2005–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Multicenter in Asia/Pacific</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2 (SD 10.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (42.2%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.0 (SD 10.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (42.2%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.6 (SD 9.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (45.9%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: dapoxetine 30 mg on‐demand, from week 4 up to 60 mg if tolerated + PDE5 inhibitor taken 1–3 hours prior to sexual intercourse </p> <p>C1: placebo daily + PDE5 inhibitor taken 1–3 hours prior to intercourse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.5 (SD 11.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (42.2%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.9 (SD 11.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (45.9%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg daily that could be titrated up to 200 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (SD 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (SD 1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg at night that could be titrated up to 100 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: fluoxetine 20 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1998–2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.4 (SD 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (SD 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.4 (SD 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (SD 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: dapoxetine 30 mg on‐demand 1–3 hours before anticipated sexual activity</p> <p>I2: dapoxetine 60 mg on‐demand 1–3 hours before anticipated sexual activity</p> <p>C1: placebo on‐demand 1–3 hours before anticipated sexual activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2003–2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.3 (SD 9.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (SD 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>563/227</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.9 (SD 9.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (SD 0.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571/234</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.3 (SD 9.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (SD 0.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560/248</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: dapoxetine 60 mg daily</p> <p>I2: paroxetine 20 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2003–2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.4 (range 20–50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (61.5%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.6 (range 21–49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (60.0%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.3 (range 21–50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (44.0%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: citalopram 30 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (21–49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (21–49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: escitalopram 10 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2003–2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.5 (range 21–44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (70%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3 (range 19–46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (69.8%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: dapoxetine 30 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.7 (range 21–54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (37.7%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3 (range 19–56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (40.6%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: citalopram 20 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.1 (SD 2.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (SD 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.8 (SD 2.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (SD 0.17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg nightly for 2 months</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.9 (median) (SD 6.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.9 (median) (SD 9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: paroxetine 20 mg daily for 1 week and then 40 mg daily from week 2–6</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (range 27–48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/8 (87.5%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (range 30–47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/9 (77.7%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>I1: fluoxetine 20 mg daily</p> <p>I2: fluvoxamine 100 mg daily</p> <p>I3: paroxetine 20 mg daily</p> <p>I4: sertraline 50 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>The Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (SD 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (SD 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (SD 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (SD 9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (SD 4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: fluoxetine 20 mg daily</p> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1997–1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.5 (range 22–56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (SD 1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.3 (range 24–58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 (SD 1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>C: comparator; I: intervention; IELT: intravaginal ejaculatory latency time; NA: not available; NR: not reported; PDE5: phosphodiesterase‐5; PE: premature ejaculation; SD: standard deviation. </p> </div> </div> <section id="CD012799-sec-0034"> <h5 class="title">Primary outcomes</h5> <p>We focused on outcomes of direct patient importance that are directly applicable to routine clinical practice using instruments that have undergone validation. </p> <p> <ul id="CD012799-list-0009"> <li> <p>Participant perception of change with treatment.</p> </li> <li> <p>Participant satisfaction with intercourse.</p> </li> <li> <p>Study withdrawal due to adverse events.</p> </li> </ul> </p> <p>We assessed participant perception of change using the Clinical Global Impression of Change (CGIC) questionnaire, which is a validated instrument that is administered after treatment (<a href="./references#CD012799-bbs2-0117" title="AlthofSE , BrockGB , RosenRC , RowlandDL , AquilinaJW , RothmanM , et al. Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation. Journal of Sexual Medicine2010;7(6):2243-52.">Althof 2010</a>). We recorded the number of participants describing the change as 'better' or 'much better' after treatment in a dichotomous manner. An event was considered 'good' as it represented 'better' or 'much better' symptoms after treatment. No minimal clinically important difference (MCID) has been reported; we considered a 10% difference between groups as clinically meaningful. This was a participant self‐reported outcome. </p> <p>We assessed participant satisfaction with intercourse using the PEP questionnaire (<a href="./references#CD012799-bbs2-0158" title="PatrickDL , GiulianoF , HoKF , GagnonDD , McNultyP , RothmanM . The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice. BJU International2009;103(3):358-64.">Patrick 2009</a>), a validated instrument that addresses four domains. We recorded the number of participants describing their satisfaction as 'good' or 'very good' before and after treatment (for satisfaction and control) in a dichotomous manner. An event was considered 'good' as it represented 'good' or 'very good' satisfaction after treatment. </p> <p>We recorded the number of participants withdrawing from the trial due to adverse events in a dichotomous manner. We considered a 5% difference between groups as clinically meaningful. This was an investigator‐assessed outcome. </p> <p>For study withdrawals due to adverse events, we considered a 2% absolute difference as clinically meaningful.  </p> <p>In the absence of any reported MCIDs for these three outcomes, all thresholds were informed by the clinical expertise and experience of the clinical authors. We did not formally involve any external stakeholders (such as men with PE) in this process. This also applies to the secondary outcomes (listed below).  </p> </section> <section id="CD012799-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012799-list-0010"> <li> <p>Perceived control over ejaculation.</p> </li> <li> <p>Participant distress about PE.</p> </li> <li> <p>Relationship difficulties.</p> </li> <li> <p>Adverse events.</p> </li> <li> <p>IELT.</p> </li> <li> <p>Depression.</p> </li> </ul> </p> <p>We also used the PEP questionnaire to assess participant satisfaction with control over ejaculation, distress about PE and relationship difficulties (<a href="./references#CD012799-bbs2-0158" title="PatrickDL , GiulianoF , HoKF , GagnonDD , McNultyP , RothmanM . The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice. BJU International2009;103(3):358-64.">Patrick 2009</a>). We recorded the number of participants describing their satisfaction as 'good' or 'very good' before and after treatment (for satisfaction and control). An event was good as it represented 'good' or 'very good' control after treatment. This was measured in a dichotomous manner. For distress and relationship difficulties, we recorded the number of participants describing their distress 'a little bit' or 'not at all.' An event was considered good as it represented 'a little bit' or 'not at all' relationship difficulties/distress after treatment. This was also measured in a dichotomous manner. No MCID has been reported; we considered a 10% difference between groups as clinically meaningful. All of these were participant self‐reported outcomes. </p> <p>We further assessed the cumulative number of adverse events in a dichotomous manner. We considered a 5% difference between groups as clinically meaningful. This was an investigator‐assessed outcome. We also provided descriptive information on the most common adverse events contributing to this analysis. </p> <p>We assessed IELT as measured using a stopwatch in minutes (<a href="./references#CD012799-bbs2-0187" title="WaldingerMD , ZwindermanAH , OlivierB , SchweitzerDH . Proposal for a definition of lifelong premature ejaculation based on epidemiological Stopwatch data. Journal of Sexual Medicine2005;2(4):498-507.">Waldinger 2005b</a>). Although this method of measurement is not routinely used in clinical practice, it represents the best current method for assessing the fundamental issue that defines PE. This was measured as a continuous outcome. No MCID has been reported in the literature. Therefore, we assumed a one‐minute difference as the smallest difference between groups to be clinically meaningful. This was based on the mean IELT; we did not use the geometric mean IELT, which has been proposed as an alternative measure more robust to non‐normal distributions (<a href="./references#CD012799-bbs2-0190" title="WaldingerMD , ZwindermanAH , OlivierB , SchweitzerDH . Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy. Journal of Sexual Medicine2008;5(2):492-9.">Waldinger 2008</a>). </p> <p>We recorded the incidence of new symptoms of depression in participants in a dichotomous manner. We looked for information using validated instruments such as the Beck Depression Inventory questionnaire (<a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>), but also recorded other types of information as collected by the investigators. No MCID has been reported; we considered a 10% difference between groups as clinically meaningful. This may have been a participant self‐reported or investigator‐assessed outcome. </p> </section> </section> </section> <section id="CD012799-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <p>A dedicated information specialist (JL) conducted all systematic searches. We applied no restrictions regarding language or publication status. </p> <section id="CD012799-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from the inception of each database. Complete search strategies for each resource are available in the Appendices. </p> <p> <ul id="CD012799-list-0011"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Library (2020, Issue 4) (<a href="./appendices#CD012799-sec-0153">Appendix 1</a>). </p> </li> <li> <p>PubMed MEDLINE (from 1946) (<a href="./appendices#CD012799-sec-0154">Appendix 2</a>). </p> </li> <li> <p>Embase via Elsevier (from 1947) (<a href="./appendices#CD012799-sec-0155">Appendix 3</a>). </p> </li> <li> <p>Cumulative Index of Nursing and Allied Health Literature (CINAHL) via EBSCOhost (from 1981) (<a href="./appendices#CD012799-sec-0156">Appendix 4</a>) </p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature (LILACS) via BIREME‐PAHO‐WHO (from 1982) (<a href="./appendices#CD012799-sec-0157">Appendix 5</a>). </p> </li> <li> <p>Scopus via Elsevier (from 1970) (<a href="./appendices#CD012799-sec-0158">Appendix 6</a>). </p> </li> <li> <p>US National Institutes of Health ClinicalTrials.gov Registry (<a href="http://ClinicalTrials.gov" target="_blank">clinicaltrials.gov</a>) (<a href="./appendices#CD012799-sec-0159">Appendix 7</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (<a href="./appendices#CD012799-sec-0160">Appendix 8</a>). </p> </li> <li> <p>ProQuest Dissertations &amp; Theses (PQDT; from 1861) (<a href="./appendices#CD012799-sec-0161">Appendix 9</a>). </p> </li> <li> <p>OCLC WorldCat Dissertations and Theses (<a href="./appendices#CD012799-sec-0162">Appendix 10</a>). </p> </li> </ul> </p> <p>We applied publication type filters as follows. For CENTRAL, we selected only clinical trials via the Cochrane Library results interface. For PubMed, we applied the Cochrane Highly Sensitive Search Strategy for identifying RCTs in MEDLINE: sensitivity‐maximizing version (2008 revision); PubMed format from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (accessed 16 June 2017). For Embase, we translated the RCT filter from SIGN (Scottish Intercollegiate Guidelines Network) (accessed from <a href="http://www.sign.ac.uk/search-filters.html" target="_blank">www.sign.ac.uk/search-filters.html</a> on 19 June 2017) to appropriate syntax for Embase‐Elsevier. For CINAHL, we used the RCT filter from SIGN (accessed from <a href="http://www.sign.ac.uk/search-filters.html" target="_blank">www.sign.ac.uk/search-filters.html</a> on 19 June 2017). We applied no filter for LILACS due to a low yield. For Scopus, as a published or validated filter was not available, the Cochrane Urology Assistant Information Specialist developed one based loosely on the CINAHL filter. No filter was needed for PQDT. For WorldCat, we selected Content Type: Thesis/Dissertation. We applied no other filters or limits to the searches. The search strategies were peer reviewed by a second Cochrane Urology Assistant Information Specialist, and recommendations were incorporated into the final strategies. </p> <p>We applied a PubMed (MEDLINE) email alert through 1 May 2020 to identify newly published trials using the same search strategy as described for MEDLINE (see <a href="./appendices#CD012799-sec-0154">Appendix 2</a> for search strategy). After we submitted the final review draft for editorial approval, the Information Specialist on our review team performed a complete search update (1 May 2020) on all databases and sent the results to the review authors. New trials were evaluated and we incorporated the findings from the new trials into our review for all included trials. </p> <p>If we detected additional relevant keywords during any electronic or other searches, we modified the electronic search strategies to incorporate these terms and documented the changes. </p> </section> <section id="CD012799-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We identified other potentially eligible trials or ancillary publications by searching the reference lists of included trials, as well as related systematic reviews, meta‐analyses and health technology assessment reports. We also contacted authors of included trials to identify additional information on the retrieved trials and any trials that we might have missed. </p> <p>We included studies presented in abstract form only as well, focusing on these relevant meetings from 2017 to 2020. For these years, abstract proceedings from can be searched and identified through electronic searches of the journals identified and captured through our electronic MEDLINE search. This included the following meetings: </p> <p> <ul id="CD012799-list-0012"> <li> <p>American Urological Association (AUA); Journal of Urology;</p> </li> <li> <p>European Urology Association (EAU); European Urology Supplements;</p> </li> <li> <p>International Society of Sexual Medicine (ISSM); Journal of Sexual Medicine;</p> </li> <li> <p>World Association for Sexual Health (WASH); Journal of Sexual Medicine;</p> </li> <li> <p>European Society for Sexual Medicine (ESSM); Journal of Sexual Medicine;</p> </li> <li> <p>World Meeting on Sexual Medicine (WMSM); Journal of Sexual Medicine;</p> </li> <li> <p>Sexual Medicine Society of North America (SMSNA); Journal of Sexual Medicine.</p> </li> </ul> </p> </section> </section> <section id="CD012799-sec-0039"> <h3 class="title" id="CD012799-sec-0039">Data collection and analysis</h3> <section id="CD012799-sec-0040"> <h4 class="title">Selection of studies</h4> <p>At least two of four review authors (RM, AS, JB, SS) independently scanned the abstract, title, or both of every record we retrieved in the literature searches, to determine which trials we should assess further. We obtained the full text of all potentially relevant records. We resolved any disagreements through consensus or by recourse to a third review author (PD). If we could not resolve a disagreement, we categorized the trial as a 'study awaiting classification' and contacted the trial authors for clarification. We presented an adapted PRISMA flow diagram to show the process of trial selection (<a href="./references#CD012799-bbs2-0149" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]">Liberati 2009</a>). </p> </section> <section id="CD012799-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>For trials that fulfilled our inclusion criteria, at least two of four review authors (RM, AS, JB, SS) independently extracted key participant and intervention characteristics. We reported data on efficacy outcomes and adverse events using standardized data extraction sheets from the Cochrane Metabolic and Endocrine Disorders Group. We resolved any disagreements by discussion or, if required, by consultation with a third review author (PD). </p> <p>We provided information about potentially relevant ongoing trials, including the trial identifier, in the Characteristics of ongoing studies table. We attempted to find the protocol for each included trial and reported primary, secondary and other outcomes. </p> <p>We emailed all authors of included trials to ask if they were willing to answer questions regarding their trials. Thereafter we requested relevant missing information on the trial from the primary trial author(s). </p> <section id="CD012799-sec-0042"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary trial, we maximized the information yielded by collating all available data and used the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial and trial documents of included trials (such as trial registry information) as secondary references under the study ID of included trials. Furthermore, we listed duplicate publications, companion documents, multiple reports of a trial and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of excluded trials. </p> </section> <section id="CD012799-sec-0043"> <h5 class="title">Data from clinical trial registers</h5> <p>If data of included trials were available as study results in clinical trial registers such as ClinicalTrials.gov, we made full use of this information and extracted the data. If there is also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trial register but no additional information was available, we added this trial to the <a href="./references#CD012799-sec-0174" title="">Characteristics of studies awaiting classification</a> table. </p> </section> </section> <section id="CD012799-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RM, SS) independently assessed the risk of bias of each included trial. We resolved any disagreements by consensus or by consulting a third review author (PD). In case of disagreement, we consulted the rest of the group and made a judgment based on consensus. If adequate information was not available from trial authors, trial protocols, or both, we contacted the trial authors for missing data on 'Risk of bias' items. </p> <p>We used the Cochrane 'Risk of bias' assessment tool and judged 'Risk of bias' criteria as low, high or unclear risk (<a href="./references#CD012799-bbs2-0138" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>; <a href="./references#CD012799-bbs2-0139" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928.">Higgins 2011b</a>). We evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> according to the criteria and associated categorizations contained therein (<a href="./references#CD012799-bbs2-0138" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>). </p> <section id="CD012799-sec-0045"> <h5 class="title">Random sequence generation (selection bias due to inadequate generation of a randomized sequence) – assessment at trial level </h5> <p>For each included trial, we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p> <ul id="CD012799-list-0013"> <li> <p>Low risk of bias: the trial authors achieved sequence generation using computer‐generated random numbers or a random numbers table. Drawing of lots, tossing a coin, shuffling cards or envelopes, and throwing dice were adequate if an independent person performed this who was not otherwise involved in the trial. We considered the use of the minimization technique as equivalent to being random. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the sequence generation process.</p> </li> <li> <p>High risk of bias: the sequence generation method was non‐random or quasi‐random (e.g. sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number; allocation by judgment of the clinician; allocation by preference of the participant; allocation based on the results of a laboratory test or a series of tests; or allocation by availability of the intervention). </p> </li> </ul> </p> </section> <section id="CD012799-sec-0046"> <h5 class="title">Allocation concealment (selection bias due to inadequate concealment of allocation prior to assignment) – assessment at trial level </h5> <p>We described for each included trial the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment. </p> <p> <ul id="CD012799-list-0014"> <li> <p>Low risk of bias: central allocation (including telephone, interactive voice‐recorder, web‐based and pharmacy‐controlled randomization); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the allocation concealment.</p> </li> <li> <p>High risk of bias: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure. </p> </li> </ul> </p> <p>We also evaluated trial baseline data to incorporate assessment of baseline imbalance into the 'Risk of bias' judgment for selection bias (<a href="./references#CD012799-bbs2-0127" title="CorbettMS , HigginsJP , WoolacottNF . Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods2014;5:79-85.">Corbett 2014</a>). Chance imbalances may also affect judgments on the risk of attrition bias. In case of unadjusted analyses, we distinguished between studies we rated at low risk of bias on the basis of both randomization methods and baseline similarity, and studies we rated at low risk of bias on the basis of baseline similarity alone (<a href="./references#CD012799-bbs2-0127" title="CorbettMS , HigginsJP , WoolacottNF . Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods2014;5:79-85.">Corbett 2014</a>). We reclassified judgments of unclear, low or high risk of selection bias. </p> </section> <section id="CD012799-sec-0047"> <h5 class="title">Blinding of participants and study personnel (performance bias due to knowledge of the allocated interventions by participants and personnel during the trial) – assessment at outcome level </h5> <p>We evaluated the risk of detection bias separately for each outcome (<a href="./references#CD012799-bbs2-0141" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201-11.">Hróbjartsson 2013</a>). We noted whether endpoints were self‐reported, investigator assessed or adjudicated outcome measures (see below). </p> <p> <ul id="CD012799-list-0015"> <li> <p>Low risk of bias: blinding of participants and key study personnel was ensured, and it was unlikely that the blinding could have been broken; no blinding or incomplete blinding, but we judged that the outcome was unlikely to have been influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the blinding of participants and study personnel; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the outcome was likely to have been influenced by lack of blinding; blinding of trial participants and key personnel attempted, but likely that the blinding could have been broken, and the outcome was likely to have been influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD012799-sec-0048"> <h5 class="title">Blinding of outcome assessment (detection bias due to knowledge of the allocated interventions by outcome assessors) – assessment at outcome level </h5> <p>We evaluated the risk of detection bias separately for each outcome (<a href="./references#CD012799-bbs2-0141" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201-11.">Hróbjartsson 2013</a>). We noted whether endpoints were self‐reported, investigator assessed or adjudicated outcome measures (see below). </p> <p> <ul id="CD012799-list-0016"> <li> <p>Low risk of bias: blinding of outcome assessment was ensured, and it was unlikely that the blinding could have been broken; no blinding of outcome assessment, but we judged that the outcome measurement was unlikely to have been influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the blinding of outcome assessors; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: no blinding of outcome assessment, and the outcome measurement was likely to have been influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD012799-sec-0049"> <h5 class="title">Incomplete outcome data (attrition bias due to amount, nature, or handling of incomplete outcome data) – assessment at outcome level </h5> <p>For each included trial for each outcome, we described the completeness of data, including attrition and exclusions from the analyses. We stated whether the trial reported attrition and exclusions, and the number of participants included in the analysis at each stage (compared with the number of randomized participants per intervention/comparator groups). We also noted if the trial reported the reasons for attrition or exclusion and whether missing data were balanced across groups or were related to outcomes. We considered the implications of missing outcome data per outcome such as high dropout rates (e.g. above 15%) or disparate attrition rates (e.g. difference of 10% or more between trial arms). </p> <p> <ul id="CD012799-list-0017"> <li> <p>Low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to introduce bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (mean difference (MD) or standardized mean difference (SMD)) among missing outcomes was not enough to have a clinically relevant impact on observed effect size; appropriate methods such as multiple imputation were used to handle missing data. </p> </li> <li> <p>Unclear risk of bias: insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to introduce bias; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: reason for missing outcome data was likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (MD or SMD) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'as‐treated' or similar analysis done with substantial departure of the intervention received from that assigned at randomization; potentially inappropriate application of simple imputation. </p> </li> </ul> </p> </section> <section id="CD012799-sec-0050"> <h5 class="title">Selective reporting (reporting bias due to selective outcome reporting) – assessment at trial level </h5> <p>We assessed outcome reporting bias by comparing the published data to the study protocol (if available). </p> <p> <ul id="CD012799-list-0018"> <li> <p>Low risk of bias: the trial protocol was available and all of the trial's prespecified (primary and secondary) outcomes that were of interest in the review were reported in the prespecified way; the study protocol was unavailable, but it was clear that the published reports included all expected outcomes (Outcome Reporting Bias in Trials (ORBIT) classification). </p> </li> <li> <p>Unclear risk of bias: insufficient information about selective reporting.</p> </li> <li> <p>High risk of bias: not all of the trial's prespecified primary outcomes were reported; one or more primary outcomes were reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse effect); one or more outcomes of interest in the Cochrane Review were reported incompletely so that we could not enter them in a meta‐analysis; the trial report failed to include results for a key outcome that would have been expected to have been reported for such a trial (ORBIT classification). </p> </li> </ul> </p> </section> <section id="CD012799-sec-0051"> <h5 class="title">Other bias (bias due to problems not covered elsewhere) – assessment at trial level</h5> <p> <ul id="CD012799-list-0019"> <li> <p>Low risk of bias: the trial appeared free of other sources of bias.</p> </li> <li> <p>Unclear risk of bias: insufficient information to assess whether an important risk of bias existed; insufficient rationale or evidence that an identified problem introduced bias. </p> </li> <li> <p>High risk of bias: the trial had a potential source of bias related to the specific trial design used; the trial was claimed to have been fraudulent; or the trial had some other serious problem. </p> </li> </ul> </p> <p>We presented a 'Risk of bias' graph and a 'Risk of bias' summary figure.</p> <p>We distinguished between self‐reported, investigator assessed, objective and adjudicated outcome measures. </p> <p>We accepted the following outcomes as self‐reported.</p> <p> <ul id="CD012799-list-0020"> <li> <p>Participant perception of change with treatment.</p> </li> <li> <p>Participant satisfaction with intercourse.</p> </li> <li> <p>Perceived control over ejaculation.</p> </li> <li> <p>Participant distress about PE.</p> </li> <li> <p>Relationship difficulties.</p> </li> <li> <p>Depression.</p> </li> </ul> </p> <p>We required the following outcomes to be investigator assessed.</p> <p> <ul id="CD012799-list-0021"> <li> <p>Study withdrawal due to adverse events.</p> </li> <li> <p>Adverse events.</p> </li> </ul> </p> <p>We classified the following outcome as objective.</p> <p> <ul id="CD012799-list-0022"> <li> <p>IELT.</p> </li> </ul> </p> <p>We did not anticipate encountering any adjudicated outcome measures.</p> </section> <section id="CD012799-sec-0052"> <h5 class="title">Summary assessment of risk of bias</h5> <section id="CD012799-sec-0053"> <h6 class="title">Risk of bias for a trial across outcomes</h6> <p>Some 'Risk of bias' domains such as selection bias (sequence generation and allocation sequence concealment) affect the risk of bias across all outcome measures in a trial. In case of high risk of selection bias, we marked all endpoints investigated in the associated trial as high risk. Otherwise, we did not perform a summary assessment of the risk of bias across all outcomes for a trial. </p> </section> <section id="CD012799-sec-0054"> <h6 class="title">Risk of bias for an outcome within a trial and across domains</h6> <p>We assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both trial‐level entries and outcome‐specific entries). We considered low risk of bias to denote a low risk of bias for all key domains; unclear risk to denote an unclear risk of bias for one or more key domains; and high risk to denote a high risk of bias for one or more key domains. </p> </section> <section id="CD012799-sec-0055"> <h6 class="title">Risk of bias for an outcome across trials and across domains</h6> <p>These are our main summary assessments, which we incorporated into our judgments about the certainty of evidence in a 'Summary of findings' table. We defined outcomes as low risk of bias when most information came from trials at low risk of bias; unclear risk when most information came from trials at low or unclear risk of bias; and high risk when a sufficient proportion of information came from trials at high risk of bias. </p> </section> </section> </section> <section id="CD012799-sec-0056"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two included trials were available for a comparison and a given outcome, we expressed dichotomous data as a risk ratio (RR) with 95% confidence interval (CI) for ease of interpretation rather than using odds ratios (ORs). For continuous outcomes measured on the same scale (e.g. weight loss in kilograms), we estimated the intervention effect using the MD with 95% CI. For continuous outcomes measuring the same underlying concept (e.g. health‐related quality of life) but using different measurement scales, we calculated the SMD with 95% CI. </p> </section> <section id="CD012799-sec-0057"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomization occurred, such as cross‐over trials, and multiple observations for the same outcome. If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we either combined groups to create a single pair‐wise comparison or appropriately reduced the sample size so that the same participants did not contribute multiple times (e.g. by splitting the 'shared' group into two or more groups). While the latter approach offers some solutions to adjusting the precision of the comparison, it does not account for correlation arising from the same set of participants being in multiple comparisons (<a href="./references#CD012799-bbs2-0138" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>). When we included cross‐over trials, we only included data from the first period to mitigate any confounding effect from carry‐over. </p> </section> <section id="CD012799-sec-0058"> <h4 class="title">Dealing with missing data</h4> <p>We obtained missing data from the authors of the included trials. We carefully evaluated important numerical data such as screened, randomly assigned participants as well as intention‐to‐treat, as‐treated and per‐protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals) and critically appraised issues concerning missing data and use of imputation methods (e.g. last observation carried forward). </p> <p>In trials where the standard deviation of the outcome was not available at follow‐up or could not be re‐created, we standardized by the mean of the pooled baseline standard deviation from those trials in which this information was reported. </p> <p>Where included trials did not report means and standard deviations for outcomes and we were unable to obtain the required information from trial authors, we imputed these values by estimating the mean and variance from the median, range and the size of the sample (<a href="./references#CD012799-bbs2-0140" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [DOI: 10.1186/1471-2288-5-13]">Hozo 2005</a>). We investigated the impact of imputation on meta‐analyses by performing sensitivity analyses and reported per outcome which trials were included with imputed standard deviations. </p> </section> <section id="CD012799-sec-0059"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of excessive clinical or methodologic heterogeneity, we would not have reported trial results as the pooled effect estimate in a meta‐analysis. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1. In view of the low power of this test, we also considered the I² statistic, which quantifies inconsistency across trials, to assess the impact of heterogeneity on the meta‐analysis. </p> <p>We interpreted the I² statistic as follows (<a href="./references#CD012799-bbs2-0135" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21:1539-58.">Higgins 2002</a>; <a href="./references#CD012799-bbs2-0136" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>; <a href="./references#CD012799-bbs2-0138" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>). </p> <p> <ul id="CD012799-list-0023"> <li> <p>0% to 40%: may not be important.</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When we found heterogeneity, we attempted to determine the possible reasons for it by examining individual trial and subgroup characteristics. </p> </section> <section id="CD012799-sec-0060"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included 10 or more trials that investigated a particular outcome, we used funnel plots to assess small‐trial effects. Several explanations can account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodologic design (and hence bias of small trials) and publication bias. Therefore, we carefully interpreted the results (<a href="./references#CD012799-bbs2-0181" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002.">Sterne 2011</a>). </p> </section> <section id="CD012799-sec-0061"> <h4 class="title">Data synthesis</h4> <p>We undertook (or displayed) a meta‐analysis only if we judged participants, interventions, comparisons and outcomes to be sufficiently similar to ensure an answer that was clinically meaningful. Unless good evidence showed homogeneous effects across trials, we primarily summarized data at low risk of bias using a random‐effects model (<a href="./references#CD012799-bbs2-0191" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>). We interpreted random‐effects meta‐analyses with due consideration to the whole distribution of effects, ideally by presenting a prediction interval (<a href="./references#CD012799-bbs2-0137" title="HigginsJP , ThompsonSG , SpiegelhalterDJ . A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society. Series A, (Statistics in Society)2009;172(1):137-59.">Higgins 2009</a>). A prediction interval specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD012799-bbs2-0164" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta-analyses. BMJ2011;342:d549.">Riley 2011</a>). For rare events such as event rates below 1%, we planned to use the Peto's OR method, provided that there was no substantial imbalance between intervention and comparator group sizes, and intervention effects were not exceptionally large. We performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012799-bbs2-0138" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>). </p> </section> <section id="CD012799-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and carried out the following subgroup analyses including investigation of interactions. </p> <p> <ul id="CD012799-list-0024"> <li> <p>Long‐acting SSRIs (e.g. paroxetine, fluoxetine, sertraline, citalopram and fluvoxamine) versus short‐acting (on‐demand type) SSRIs (e.g. dapoxetine). We compared the long‐ versus short‐acting SSRIs because not only may there be a difference in efficacy, but the incidence of adverse effects may vary by taking SSRIs daily rather than on‐demand. </p> </li> <li> <p>Among the long‐acting SSRIs, comparison of individual agents (e.g. paroxetine versus fluoxetine versus sertraline versus citalopram versus fluvoxamine). We compared these agents because although they are from the same class, there is evidence to suggest that they have varying efficacy and adverse effect profile (<a href="./references#CD012799-bbs2-0172" title="SanchezC , ReinesEH , MontgomerySA . A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?International Clinical Psychopharmacology2014;29(4):185-96.">Sanchez 2014</a>) </p> </li> <li> <p>If applicable, different dose levels (e.g. dapoxetine 30 mg versus 60 mg). Dose levels are compared because the use of SSRIs in PE is an off‐label indication and there is no clear evidence on the optimal dosage for the best trade‐off of benefit versus risk. </p> </li> </ul> </p> </section> <section id="CD012799-sec-0063"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis to explore the influence of the following factors (when applicable) on effect sizes by restricting analysis to the following. </p> <p> <ul id="CD012799-list-0025"> <li> <p>Taking into account risk of bias, as specified in the <a href="#CD012799-sec-0044">Assessment of risk of bias in included studies</a> section, by removing studies judged at high risk of bias. </p> </li> </ul> </p> </section> <section id="CD012799-sec-0064"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account issues related to internal validity (risk of bias, inconsistency, imprecision, publication bias) and external validity, such as directness of results<i>.</i> Two review authors (RM, PD) independently rated the certainty of the evidence for each outcome. </p> <p>We presented a summary of the evidence in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome, and rating of overall confidence in effect estimates for each outcome. We created the 'Summary of findings' table based on the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> by means of the table editor in Review Manager 5 (<a href="./references#CD012799-bbs2-0163" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We used GRADEpro GDT software and present evidence profile tables as an appendix (<a href="./references#CD012799-bbs2-0133" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version (accessed 5 July 2017). Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>). We presented results for the outcomes as described in the <a href="#CD012799-sec-0033">Types of outcome measures</a> section. If meta‐analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' table. We justified all decisions to downgrade the certainty of studies using footnotes, and made comments to aid the reader's understanding of the Cochrane Review where necessary. </p> <p>The 'Summary of findings' table includes following outcomes, listed according to priority.</p> <p> <ol id="CD012799-list-0026"> <li> <p>Participant perception of change with treatment.</p> </li> <li> <p>Participant satisfaction with intercourse.</p> </li> <li> <p>Study withdrawal due to adverse events.</p> </li> <li> <p>Perceived control over ejaculation.</p> </li> <li> <p>Participant distress about PE.</p> </li> <li> <p>Adverse events.</p> </li> <li> <p>IELT.</p> </li> </ol> </p> <p>Although we did not include relationship difficulties and depression as outcomes in the 'Summary of findings' table (due to a limit of seven outcomes), we provided the same type of analysis in the <a href="./full#CD012799-sec-0065">Results</a> section and also rated the certainty of the evidence using GRADE for these outcomes.  </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012799-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012799-sec-0065"></div> <section id="CD012799-sec-0066"> <h3 class="title">Description of studies</h3> <p>We presented details of included studies in the <a href="./references#CD012799-sec-0172" title="">Characteristics of included studies</a> and <a href="#CD012799-tbl-0002">Table 1</a> and <a href="#CD012799-tbl-0003">Table 2</a>. </p> <section id="CD012799-sec-0067"> <h4 class="title">Results of the search</h4> <p>Our search of multiple electronic databases up to May 2020 yielded 1218 references (<a href="#CD012799-fig-0001">Figure 1</a>). After exclusion of duplicates, we screened 922 references at the title/abstract stage. Subsequently after screening titles/abstracts, 124 unique studies entered the full‐text screening stage. We included 31 studies (40 records) in the quantitative analyses. We summarized reasons for exclusion at the full‐text stage in the PRISMA flow diagram (<a href="#CD012799-fig-0001">Figure 1</a>), and we provided further details <a href="./references#CD012799-sec-0173" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD012799-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012799-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012799-sec-0068"> <h4 class="title">Included studies</h4> <section id="CD012799-sec-0069"> <h5 class="title">Source of data</h5> <p>We included 29 studies published in full‐text and two additional studies only available as abstract proceedings (<a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a>; <a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a>), for a total of 31 unique studies. Two studies were published in Korean (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>; <a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a>), and two studies were published in Chinese (<a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>). One review author (ECH) translated the Korean studies into English and Dr Yu Xie translated the Chinese studies into English. The remaining 27 studies were published in English. </p> </section> <section id="CD012799-sec-0070"> <h5 class="title">Study design and settings</h5> <p>Four studies were cross‐over trials (<a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a>; <a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a>; <a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>), and remaining studies were parallel, RCTs. All studies were likely conducted in an outpatient clinic setting. </p> </section> <section id="CD012799-sec-0071"> <h5 class="title">Participants</h5> <p>We included 8254 randomized participants (SSRI 4990, placebo 2928, other drug 131). Two studies did not report the number of participants in each arm (<a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>). All studies included sexually active men aged over 18 years with PE. </p> </section> <section id="CD012799-sec-0072"> <h5 class="title">Interventions and comparators</h5> <p>Studies used a range of SSRIs with different doses. Seven studies used fluoxetine (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>; <a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>), one used duloxetine (<a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>), three used citalopram (<a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>), seven used sertraline (<a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a>; <a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a>; <a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a>; <a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>), seven used dapoxetine (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>), eight used paroxetine (<a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a>; <a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a>; <a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a>; <a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>), one used escitalopram (<a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>), and one used fluvoxamine (<a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>). </p> <p>All studies used placebo as the comparator.</p> </section> <section id="CD012799-sec-0073"> <h5 class="title">Outcomes</h5> <p>For our predefined primary outcomes, six studies reported participant perception of change with treatment (<a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>; <a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>), three reported participant satisfaction with intercourse (<a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>), and 20 studies reported study withdrawal due to adverse events (<a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>; <a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a>; <a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a>; <a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>; <a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>). </p> <p>In terms of predefined secondary outcomes, three studies reported perceived control over ejaculation (<a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>), 17 reported adverse events (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>; <a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>; <a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a>; <a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>; <a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>), 20 reported IELT (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>; <a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>; <a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a>; <a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a>; <a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a>; <a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>; <a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>), and one reported depression (<a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>). One study reported participant distress about PE and relationship difficulties (<a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>) </p> <p>Please refer to <a href="./references#CD012799-fig-0007" title="">Analysis 1.1</a> through <a href="./references#CD012799-fig-0015" title="">Analysis 1.9</a>. </p> </section> <section id="CD012799-sec-0074"> <h5 class="title">Funding sources and conflicts of interest</h5> <p>Four studies reported no funding source (<a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>), and pharmaceutical companies supported seven studies (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>). The remaining studies did not address their funding source<i>.</i> </p> <p>Two studies reported no conflicts of interest (<a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>), and six studies reported investigators having relationships with pharmaceutical companies (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>). The remaining studies did not address conflicts of interest. </p> </section> </section> <section id="CD012799-sec-0075"> <h4 class="title">Excluded studies</h4> <p>We excluded 84 records after evaluation of the full‐text publications for which we presented details in the <a href="./references#CD012799-sec-0173" title="">Characteristics of excluded studies</a> table. </p> <section id="CD012799-sec-0076"> <h5 class="title">Studies awaiting classification</h5> <p>We found one study awaiting classification that has not provided usable outcome data at this time (<a href="./references#CD012799-bbs2-0116" title="KolomazníkM , ČervinkaL , Kutílek Š, PohankaM , SkibováJ , TaušL , et al. Fluoxetine in the treatment of ejaculatio praecox. Psychiatrie2002;6(1):6-9. ">Kolomazník 2002</a>; see <a href="./references#CD012799-sec-0174" title="">Characteristics of studies awaiting classification</a> table). </p> </section> <section id="CD012799-sec-0077"> <h5 class="title">Ongoing trials</h5> <p>We identified no ongoing studies.</p> </section> </section> </section> <section id="CD012799-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the risk of bias in included studies are provided graphically in <a href="#CD012799-fig-0002">Figure 2</a> and <a href="#CD012799-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012799-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD012799-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012799-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD012799-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012799-sec-0079"> <h4 class="title">Allocation</h4> <section id="CD012799-sec-0080"> <h5 class="title">Random sequence generation</h5> <p>Eleven of 31 studies were at low risk of bias because they employed an appropriate method of generating a random sequence (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>). The remaining 20 studies were at unclear risk because they did not explicitly describe the method of random sequence generation (<a href="#CD012799-fig-0002">Figure 2</a>; <a href="#CD012799-fig-0003">Figure 3</a>). </p> </section> <section id="CD012799-sec-0081"> <h5 class="title">Allocation concealment</h5> <p>Eight of 31 studies were at low risk of bias because they implemented appropriate mechanisms to ensure that individuals enrolling participants were unaware of the upcoming group assignment for that participant (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>). The 23 remaining studies were at unclear risk because they did not explicitly describe the methods utilized to ensure allocation concealment (<a href="#CD012799-fig-0002">Figure 2</a>; <a href="#CD012799-fig-0003">Figure 3</a>). </p> </section> </section> <section id="CD012799-sec-0082"> <h4 class="title">Blinding</h4> <section id="CD012799-sec-0083"> <h5 class="title">Blinding of participants and personnel</h5> <p>Fifteen of 31 studies appropriately blinded both participants and personnel and were at low risk of bias (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>; <a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>; <a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>). Twelve studies were at unclear risk of bias because they did not clearly describe which party was blinded (<a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>; <a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a>; <a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a>; <a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a>; <a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a>; <a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>). Four studies were at high risk of bias because they were single‐blind in which personnel were not blinded (<a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a>; <a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a>; <a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a>). (<a href="#CD012799-fig-0002">Figure 2</a>; <a href="#CD012799-fig-0003">Figure 3</a>). </p> </section> <section id="CD012799-sec-0084"> <h5 class="title">Blinding of outcome assessment</h5> <p>For participant‐reported outcomes, 26 studies were at low risk of bias because participants appeared to adequately blinded and five studies were at unclear risk of bias (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a>; <a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a>; <a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a>; <a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a>). No study was at high risk (<a href="#CD012799-fig-0002">Figure 2</a>; <a href="#CD012799-fig-0003">Figure 3</a>). </p> <p>For investigator‐assessed outcomes, seven studies were at low risk of bias because the outcome assessors were adequately blinded (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>; <a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>). Twenty studies were at unclear risk because it was not clearly described whether outcome assessors were blinded (<a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>; <a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a>; <a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a>; <a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a>; <a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a>; <a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>; <a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>) Four studies were at high risk of bias because the investigators were not blinded (<a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a>; <a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a>; <a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a>). (<a href="#CD012799-fig-0002">Figure 2</a>; <a href="#CD012799-fig-0003">Figure 3</a>). </p> <p>All studies were at low risk of bias for the IELT outcome because this is an objectively assessed measure that would have been expected to be affected by blinding or lack thereof in terms of detection bias (<a href="#CD012799-fig-0002">Figure 2</a>; <a href="#CD012799-fig-0003">Figure 3</a>). </p> </section> </section> <section id="CD012799-sec-0085"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed the risk of attrition bias on a per‐outcome basis but then collapsed these rating into one group since all judgments were identical. Twelve studies were at low risk of bias (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>; <a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a>; <a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>; <a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a>). Thirteen studies were at unclear risk of bias as the proportion of randomized participants not included in the analyses was not clearly reported and the risk of attrition bias could not be estimated (<a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>; <a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a>; <a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a>; <a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>). Six studies were at high risk of bias because large proportions of participants were excluded from the final analysis (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a>; <a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a>). </p> </section> <section id="CD012799-sec-0086"> <h4 class="title">Selective reporting</h4> <p>Four studies were at low risk of bias as they reported all outcomes according to their protocol and conducted their analyses according to their a priori plans (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>). Twenty‐five studies were at unclear risk of bias because the no study protocols were available (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>; <a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>; <a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a>; <a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a>; <a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a>; <a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a>; <a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a>; <a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a>; <a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>; <a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a>; <a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a>; <a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>; <a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a><a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>; <a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a>; <a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>). Two studies were at high risk of bias because one did not complete report outcomes on one of their group (<a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>), and another did not completely report on side effects (<a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>) (<a href="#CD012799-fig-0002">Figure 2</a>; <a href="#CD012799-fig-0003">Figure 3</a>). </p> </section> <section id="CD012799-sec-0087"> <h4 class="title">Other potential sources of bias</h4> <p>Twenty‐seven studies were at low risk of bias (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>; <a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>; <a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>; <a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a>; <a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a>; <a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a>; <a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a>; <a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a>; <a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a>; <a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a>; <a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a>; <a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>; <a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a>; <a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a>; <a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>). Three studies were at unclear risk of bias because there was imbalance in the baseline characteristics (<a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a>), or they were only reported in abstract form and there was insufficient information to make a judgment (<a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a>; <a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a>). One study was at high risk of bias because it only evaluated specific adverse effects (<a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>) (<a href="#CD012799-fig-0002">Figure 2</a>; <a href="#CD012799-fig-0003">Figure 3</a>). </p> </section> </section> <section id="CD012799-sec-0088"> <h3 class="title" id="CD012799-sec-0088">Effects of interventions</h3> <p>See: <a href="./full#CD012799-tbl-0001"><b>Summary of findings 1</b> SSRI compared to placebo for premature ejaculation</a> </p> <section id="CD012799-sec-0089"> <h4 class="title">Primary outcomes</h4> <section id="CD012799-sec-0090"> <h5 class="title">1.1 Participant perception of change with treatment</h5> <p>SSRI treatment probably results in an improvement in PE‐related symptoms defined as a rating of 'better' or 'much better' using the CGIC questionnaire compared to placebo (RR 1.92, 95% CI 1.66 to 2.23; I² = 24%; studies = 6, participants = 3260; <a href="./references#CD012799-fig-0007" title="">Analysis 1.1</a>; <a href="#CD012799-fig-0004">Figure 4</a>). Compared to placebo and a baseline risk of 220 per 1000 men, this corresponds to 202 more men per 1000 (95% CI 145 more to 270 more) perceiving that their condition as 'better' or 'much better' with SSRIs. </p> <div class="figure" id="CD012799-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.1 Participant perception of change with treatment." data-id="CD012799-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.1 Participant perception of change with treatment. </p> </div> </div> </div> <p>We rated the certainty of evidence as moderate, downgrading one level due to serious study limitations given that of the six studies included in this analysis, four had an unclear risk of selection bias, three had an unclear risk of performance bias and one had an unclear risk of detection bias. In addition, two were at high risk for attrition bias. </p> </section> <section id="CD012799-sec-0091"> <h5 class="title">1.2 Participant satisfaction with intercourse</h5> <p>SSRI treatment probably improves satisfaction with intercourse defined as a rating of 'good' or 'very good' using the CGIC questionnaire compared to placebo (RR 1.63, 95% CI 1.42 to 1.87; I² = 53%; studies = 3, participants = 4273; <a href="./references#CD012799-fig-0008" title="">Analysis 1.2</a>; <a href="#CD012799-fig-0005">Figure 5</a>). Compared to placebo and a baseline risk of 278 per 1000 men, this corresponds to 175 more men per 1000 (95% CI 117 more to 242 more) describing their satisfaction with intercourse as being 'good' or 'very good' with SSRIs. </p> <div class="figure" id="CD012799-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.2 Participant satisfaction with intercourse." data-id="CD012799-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.2 Participant satisfaction with intercourse. </p> </div> </div> </div> <p>We rated the certainty of evidence as moderate, downgrading one level due to serious study limitations. Two of three included studies were at unclear risk of selection bias, one was at unclear risk of performance bias and one study that contributed a weight of 61.6% to the analysis was at high risk of attrition bias. However, we did not downgrade for the I² statistic of 53% since we did not judge the observed inconsistency to be clinically relevant. </p> </section> <section id="CD012799-sec-0092"> <h5 class="title">1.3 Study withdrawal due to adverse events</h5> <p>SSRI treatment may result in an increase in the number of treatment cessations due to adverse events compared to placebo (RR 3.80, 95% CI 2.61 to 5.51; I² = 0%; studies = 20, participants = 7367; <a href="./references#CD012799-fig-0009" title="">Analysis 1.3</a>; <a href="#CD012799-fig-0006">Figure 6</a>). Compared to placebo and a baseline risk of 11 per 1000 men, this corresponds to 30 more men per 1000 (95% CI 17 more to 49 more) stopping treatment due to adverse events due to SSRI treatment. </p> <div class="figure" id="CD012799-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.3 Study withdrawal due to adverse events." data-id="CD012799-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.3 Study withdrawal due to adverse events. </p> </div> </div> </div> <p>We rated the certainty of evidence as low, downgrading two levels due to very serious study limitations because more than half the included studies were at unclear risk of selection bias or performance bias, or both. Four studies were at high risk of attrition bias for this outcome and two studies were at high risk of selective reporting bias. </p> </section> </section> <section id="CD012799-sec-0093"> <h4 class="title">Secondary outcomes</h4> <section id="CD012799-sec-0094"> <h5 class="title">1.4 Perceived control over ejaculation</h5> <p>SSRI treatment probably improves participants' control over ejaculation defined as a rating of 'good' or 'very good' based on the PEP questionnaire compared to placebo (RR 2.29, 95% CI 1.72 to 3.05; I² = 75%; studies = 3, participants = 4273; <a href="./references#CD012799-fig-0010" title="">Analysis 1.4</a>). Compared to placebo and a baseline risk of 132 per 1000 men, this corresponds to 170 more men per 1000 (95% CI 95 more to 270 more) describing their control over ejaculation as being 'good' or 'very good' with SSRIs. </p> <p>We rated the certainty of evidence as moderate, downgrading one level due to serious study limitations. Two of three studies had an unclear risk of selection bias, one had an unclear risk of performance bias and one had a high risk of attrition bias. </p> </section> <section id="CD012799-sec-0095"> <h5 class="title">1.5 Participant distress about premature ejaculation</h5> <p>SSRI treatment probably decreases PE‐related distress defined as 'a little bit' or 'not at all' distressing based on the PEP questionnaire compared to placebo (RR 1.54, 95% CI 1.26 to 1.88; studies = 1, participants = 652; <a href="./references#CD012799-fig-0011" title="">Analysis 1.5</a>). Compared to placebo and a baseline risk of 353 per 1000 men, this corresponds to 191 men more per 1000 (95% CI 92 more to 311 more) reporting their distress about PE as being only 'a little bit' or 'not at all' with SSRIs. </p> <p>We rated the certainty of evidence as moderate, downgrading one level due to serious study limitations because the only included study had unclear risk of selection bias, an unclear risk of attrition bias and a high risk of selective reporting bias. </p> </section> <section id="CD012799-sec-0096"> <h5 class="title">1.6 Relationship difficulties</h5> <p>SSRI treatment may reduce relationship difficulties to only 'a little bit' or 'not at all' based on the PEP questionnaire compared to placebo (RR 1.20, 95% CI 1.07 to 1.34; studies = 1, participants = 652; <a href="./references#CD012799-fig-0012" title="">Analysis 1.6</a>). Compared to placebo, this corresponds to 129 men more per 1000 (95% CI 45 more to 218 more) reporting their relationship difficulties as being only 'a little bit' or 'not at all' with SSRIs. </p> <p>We rated the certainty of evidence as low, downgrading one level each for serious study limitations and imprecision. The only included study had an unclear risk of selection bias, an unclear risk of attrition bias and a high risk of selective reporting bias. We perceived the absolute effect size to cross the threshold for a clinically important difference of 10% and, therefore, downgraded a further level for imprecision. </p> </section> <section id="CD012799-sec-0097"> <h5 class="title">1.7 Adverse events</h5> <p>SSRI treatment probably increases adverse events substantially compared to placebo (RR 1.71, 95% CI 1.48 to 1.99; I² = 41%; studies = 17, participants = 4624; <a href="./references#CD012799-fig-0013" title="">Analysis 1.7</a>). Compared to placebo and a baseline risk of 243 per 1000, this corresponds to 173 more adverse events per 1000 men (95% CI 117 more to 241 more). </p> <p>We rated the certainty of evidence as moderate, downgrading one level due to serious study limitations because more than half the included studies were rated as unclear risk for selection bias or performance bias, or both. Two studies had a high risk of attrition bias and over half had an unclear risk of selective reporting bias. </p> </section> <section id="CD012799-sec-0098"> <h5 class="title">1.8 Intravaginal ejaculatory latency time</h5> <p>SSRI treatment may increase IELT compared to placebo (MD 3.09 minutes longer, 95% CI 1.94 longer to 4.25 longer; I² = 99%; studies = 20, participants = 5872; <a href="./references#CD012799-fig-0014" title="">Analysis 1.8</a>). </p> <p>We rated the certainty of evidence as low, downgrading one level due to serious study limitations; most studies had an unclear or high risk of selection, performance, attrition and reporting bias. We also downgraded one level for serious concerns about inconsistency. These may in part be attributable to the duration of action (long versus short acting; <a href="./references#CD012799-fig-0028" title="">Analysis 3.4</a>) and type of SSRI (<a href="./references#CD012799-fig-0028" title="">Analysis 3.4</a>). </p> </section> <section id="CD012799-sec-0099"> <h5 class="title">1.9 Depression</h5> <p>We are very uncertain whether SSRI treatment compared to placebo increases depression (RR 2.00, 95% CI 0.23 to 17.34; studies = 1, participants = 14; <a href="./references#CD012799-fig-0015" title="">Analysis 1.9</a>). We rated the certainty of evidence as very low, downgrading due to serious study limitations (unclear risk of selection and performance bias, high risk of attrition bias and unclear risk of selective reporting bias) and very serious imprecision. </p> </section> </section> <section id="CD012799-sec-0100"> <h4 class="title">Subgroup analyses</h4> <section id="CD012799-sec-0101"> <h5 class="title">2 Long‐acting versus short‐acting SSRIs</h5> <section id="CD012799-sec-0102"> <h6 class="title">2.1 Participant perception of change with treatment</h6> <p>The RR for participant perception of change with treatment as being 'better' or 'much better' was 8.48 (95% CI 2.21 to 32.51) for long‐acting SSRIs and 1.87 (95% CI 1.66 to 2.10) for short‐acting SSRIs (<a href="./references#CD012799-fig-0016" title="">Analysis 2.1</a>). The test for interaction was significant (P = 0.03; I² = 79.3%). </p> </section> <section id="CD012799-sec-0103"> <h6 class="title">2.2 Participant satisfaction with intercourse</h6> <p>There were no studies of long‐acting SSRIs that evaluated participant satisfaction with intercourse. </p> </section> <section id="CD012799-sec-0104"> <h6 class="title">2.3 Study withdrawal due to adverse events</h6> <p>The RR for study withdrawal due to adverse events was 2.00 (95% CI 0.92 to 4.34) for long‐acting SSRIs and 4.33 (95% CI 2.60 to 7.23) for short‐acting SSRIs (<a href="./references#CD012799-fig-0018" title="">Analysis 2.3</a>). The test for interaction was not significant (P = 0.10; I² = 62.4%). </p> </section> <section id="CD012799-sec-0105"> <h6 class="title">2.4 Perceived control over ejaculation</h6> <p>There were no studies of long‐acting SSRIs that evaluated perceived control over ejaculation.</p> </section> <section id="CD012799-sec-0106"> <h6 class="title">2.5 Participant distress about premature ejaculation</h6> <p>There were no studies of long‐acting SSRIs that evaluated participant distress about PE. </p> </section> <section id="CD012799-sec-0107"> <h6 class="title">2.6 Relationship difficulties</h6> <p>There were no studies of long‐acting SSRIs that evaluated relationship difficulties.</p> </section> <section id="CD012799-sec-0108"> <h6 class="title">2.7 Adverse events</h6> <p>The RR for adverse events was 1.90 (95% CI 1.37 to 2.64) for long‐acting SSRIs and 1.70 (95% CI 1.42 to 2.03) for short‐acting SSRIs (<a href="./references#CD012799-fig-0022" title="">Analysis 2.7</a>). The test for interaction was not significant (P = 0.54; I² = 0%). </p> </section> <section id="CD012799-sec-0109"> <h6 class="title">2.8 Intravaginal ejaculatory latency time</h6> <p>The MD for IELT was 3.36 minutes (95% CI 1.62 to 5.10) for long‐acting SSRIs and 1.52 minutes (95% CI 1.27 to 1.77) for short‐acting SSRIs (<a href="./references#CD012799-fig-0023" title="">Analysis 2.8</a>). The test for interaction was significant (P = 0.04; I² = 76.2%). </p> </section> <section id="CD012799-sec-0110"> <h6 class="title">2.9 Depression</h6> <p>There were no studies of short‐acting SSRIs that evaluated depression.</p> </section> </section> <section id="CD012799-sec-0111"> <h5 class="title">3 Types of long‐acting SSRIs</h5> <section id="CD012799-sec-0112"> <h6 class="title">3.1 Participant perception of change with treatment</h6> <p>We found one study of citalopram (<a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a>) and one of duloxetine (<a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a>), which evaluated participant perception of change with treatment. The RR for participant perception of change with treatment as being 'better' or 'much better' was 9.00 (95% CI 1.32 to 61.24) for citalopram and 8.00 (95% CI 1.21 to 52.69) for duloxetine (<a href="./references#CD012799-fig-0025" title="">Analysis 3.1</a>). The test for interaction was not significant (P = 0.93; I² = 0%). </p> </section> <section id="CD012799-sec-0113"> <h6 class="title">3.2 Participant satisfaction with intercourse</h6> <p>There were no studies of long‐acting SSRIs that evaluated participant satisfaction with intercourse. </p> </section> <section id="CD012799-sec-0114"> <h6 class="title">3.3 Study withdrawal due to adverse events</h6> <p>We found 14 studies of long‐acting SSRIs that evaluated this outcome.</p> <p>The RR for study withdrawal due to adverse events was 3.00 (95% CI 0.13 to 70.74) for citalopram, 7.64 (95% CI 0.99 to 58.71) for dapoxetine, not estimable for duloxetine, 2.00 (95% CI 0.37 to 10.74) for escitalopram, 2.59 (95% CI 0.34 to 19.59) for fluoxetine, 1.54 (95% CI 0.09 to 25.86) for fluvoxamine, 1.76 (95% CI 0.35 to 8.91) for paroxetine and 0.43 (95% CI 0.05 to 3.56) for sertraline (<a href="./references#CD012799-fig-0026" title="">Analysis 3.2</a>). The test for interaction was not significant (P = 0.69; I² = 0%). </p> </section> <section id="CD012799-sec-0115"> <h6 class="title">3.4 Perceived control over ejaculation</h6> <p>There were no studies of long‐acting SSRIs that evaluated perceived control over ejaculation.</p> </section> <section id="CD012799-sec-0116"> <h6 class="title">3.5 Participant distress about premature ejaculation</h6> <p>There were no studies of long‐acting SSRIs that evaluated participant distress about PE. </p> </section> <section id="CD012799-sec-0117"> <h6 class="title">3.6 Relationship difficulties</h6> <p>There were no studies of long‐acting SSRIs that evaluated relationship difficulties.</p> </section> <section id="CD012799-sec-0118"> <h6 class="title">3.7 Adverse events</h6> <p>We found 13 studies of long‐acting SSRIs that evaluated adverse effects. The RR for adverse effects was 3.00 (95% CI 0.51 to 17.57) for citalopram, 4.40 (95% CI 1.06 to 18.32) for clomipramine, 2.54 (95% CI 1.34 to 4.81) for dapoxetine, 3.00 (95% CI 0.37 to 24.17) for duloxetine, 1.69 (95% CI 0.69 to 4.15) for escitalopram, 2.50 (95% CI 1.29, to 4.86) for fluoxetine, 2.50 (95% CI 0.91 to 6.90) for paroxetine and 1.33 (95% CI 0.74 to 2.39) for sertraline (<a href="./references#CD012799-fig-0027" title="">Analysis 3.3</a>). The test for interaction was not significant (P = 0.71; I² = 0%). </p> </section> <section id="CD012799-sec-0119"> <h6 class="title">3.8 Intravaginal ejaculatory latency time</h6> <p>We found 14 studies of long‐acting SSRIs that evaluated IELT. The MD for IELT was 4.85 (95% CI 3.14 to 6.56) for citalopram, 1.52 (95% CI 0.80 to 2.24) for duloxetine, 2.46 (95% CI 1.51 to 3.39) for fluoxetine, 0.59 (95% CI –0.35 to 1.53) for fluvoxamine, 6.51 (95% CI 0.33 to 12.68) for paroxetine and 2.55 (95% CI 1.54 to 3.56) for sertraline (<a href="./references#CD012799-fig-0028" title="">Analysis 3.4</a>). The test for interaction was significant (P &lt; 0.001, I² = 80.0%). </p> </section> <section id="CD012799-sec-0120"> <h6 class="title">3.9 Depression</h6> <p>We only found one study using long‐acting fluoxetine that evaluated depression and were unable to perform any secondary analyses (<a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>). </p> </section> </section> <section id="CD012799-sec-0121"> <h5 class="title">4 Different doses: dapoxetine</h5> <section id="CD012799-sec-0122"> <h6 class="title">4.1 Participant perception of change with treatment</h6> <p>We found four studies that administered dapoxetine at the following doses: 30 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>), 30 mg on‐demand (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>), 60 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>), and 60 mg on‐demand (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>). The RR for participant perception of change with treatment as being 'better' or 'much better' was 1.87 (95% CI 1.37 to 2.54) with 30 mg daily, 2.00 (95% CI 1.33 to 3.01) with 30 mg on‐demand, 1.68 (95% CI 1.23 to 2.30) with 60 mg daily and 1.98 (95% CI 1.58 to 2.48) with 60 mg on‐demand (<a href="./references#CD012799-fig-0030" title="">Analysis 4.1</a>). The test for interaction was not significant (P = 0.85; I² = 0%). </p> </section> <section id="CD012799-sec-0123"> <h6 class="title">4.2 Participant satisfaction with intercourse</h6> <p>We found three studies that administered dapoxetine at the following doses: 30 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>), 30 mg on‐demand (<a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>), 60 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>), and 60 mg on‐demand (<a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>). The RR for participant satisfaction with intercourse defined as a rating of 'good' or 'very good' was 1.41 (95% CI 1.08 to 1.85) with 30 mg daily, 1.59 (95% CI 1.33 to 1.90) with 30 mg on‐demand, 1.39 (95% CI 1.07 to 1.82) with 60 mg daily and 1.61 (95% CI 1.32 to 1.98) with 60 mg on‐demand (<a href="./references#CD012799-fig-0031" title="">Analysis 4.2</a>). The test for interaction was not significant (P = 0.74; I² = 0%). </p> </section> <section id="CD012799-sec-0124"> <h6 class="title">4.3 Study withdrawal due to adverse events</h6> <p>We found three studies that administered dapoxetine at the following doses: 30 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>), 30 mg on‐demand (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>), 60 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>), and 60 mg on‐demand (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>). The RR for study withdrawal due to adverse events was 3.03 (95% CI 0.37 to 25.01) with 30 mg daily, 2.44 (95% CI 1.06 to 5.59) with 30 mg on‐demand, 8.76 (95% CI 2.10 to 36.49) with 60 mg daily and 6.51 (95% CI 3.64 to 11.66) with 60 mg on‐demand (<a href="./references#CD012799-fig-0032" title="">Analysis 4.3</a>). The test for interaction was not significant (P = 0.22, I² = 33%). </p> </section> <section id="CD012799-sec-0125"> <h6 class="title">4.4 Perceived control over ejaculation</h6> <p>We found three studies that administered dapoxetine at the following doses: 30 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>), 30 mg on‐demand (<a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>), 60 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>), and 60 mg on‐demand (<a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>). The RR of participants' control over ejaculation defined as a rating of 'good' or 'very good' was 1.79 (95% CI 1.26 to 2.53) with 30 mg daily, 3.70 (95% CI 2.72 to 5.04) with 30 mg on‐demand, 1.78 (95% CI 1.26 to 2.52) with 60 mg daily and 2.28 (95% CI 1.65 to 3.16) with 60 mg on‐demand (<a href="./references#CD012799-fig-0033" title="">Analysis 4.4</a>). The test for interaction was significant (P = 0.004; I² = 77.2%). </p> </section> <section id="CD012799-sec-0126"> <h6 class="title">4.5 Participant distress about premature ejaculation</h6> <p>We found one study that administered dapoxetine 60 mg on‐demand (<a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>). The RR for PE‐related distress defined as a rating of its severity of only 'a little bit' or 'not at all' was 1.54 (95% CI 1.26 to 1.88; <a href="./references#CD012799-fig-0034" title="">Analysis 4.5</a>). We could not test for subgroup differences. </p> </section> <section id="CD012799-sec-0127"> <h6 class="title">4.6 Relationship difficulties</h6> <p>We found one study that administered dapoxetine 60 mg on‐demand (<a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>). The RR for reducing relationship difficulties to only 'a little bit' or 'not at all' with this study was 1.20 (95% CI 1.07 to 1.34; <a href="./references#CD012799-fig-0035" title="">Analysis 4.6</a>). We could not test for subgroup differences. </p> </section> <section id="CD012799-sec-0128"> <h6 class="title">4.7 Adverse events</h6> <p>We found five studies that administered dapoxetine at the following doses: 30 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>), 30 mg on‐demand (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>), 60 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>; <a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>), and 60 mg on‐demand (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a>). The RR for adverse events was 1.64 (95% CI 1.30 to 2.07) with 30 mg daily, 1.47 (95% CI 1.20 to 1.79) with 30 mg on‐demand, 2.73 (95% CI 2.03 to 3.66) with 60 mg daily and 1.56 (95% CI 1.23 to 1.99) with 60 mg on‐demand (<a href="./references#CD012799-fig-0036" title="">Analysis 4.7</a>). The test for interaction was significant (P = 0.006; I² = 76.2%). </p> </section> <section id="CD012799-sec-0129"> <h6 class="title">4.8 Intravaginal ejaculatory latency time</h6> <p>We found four studies that administered dapoxetine as the following doses: 30 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>), 30 mg on‐demand (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>), 60 mg daily (<a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a>), and 60 mg on‐demand (<a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a>; <a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a>). The MD for IELT was 1.80 (95% CI 1.27 to 2.33) with 30 mg daily, 1.37 (95% CI 0.86 to 1.89) with 30 mg on‐demand, 1.50 (95% CI 0.98 to 2.02) with 60 mg daily and 1.53 (95% CI 1.09 to 1.97) with 60 mg on‐demand (<a href="./references#CD012799-fig-0037" title="">Analysis 4.8</a>). The test for interaction was not significant (P = 0.71, I² = 0%). </p> </section> <section id="CD012799-sec-0130"> <h6 class="title">4.9 Depression</h6> <p>We found no studies using dapoxetine that evaluated depression.</p> </section> </section> <section id="CD012799-sec-0131"> <h5 class="title">5 Different doses: fluoxetine</h5> <section id="CD012799-sec-0132"> <h6 class="title">5.1 Participant perception of change with treatment</h6> <p>We found no studies using fluoxetine that evaluated participant perception of change with treatment. </p> </section> <section id="CD012799-sec-0133"> <h6 class="title">5.2 Participant satisfaction with intercourse</h6> <p>We found no studies using fluoxetine that evaluated participant satisfaction with intercourse. </p> </section> <section id="CD012799-sec-0134"> <h6 class="title">5.3 Study withdrawal due to adverse events</h6> <p>We found three studies that administered fluoxetine 20 mg daily (<a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>). The RR for study withdrawal due to adverse events using this dose was 2.09 (95% CI 0.26 to 16.82; <a href="./references#CD012799-fig-0038" title="">Analysis 5.1</a>). We could not test for subgroup differences. </p> </section> <section id="CD012799-sec-0135"> <h6 class="title">5.4 Perceived control over ejaculation</h6> <p>We found no studies using fluoxetine that evaluated perceived control over ejaculation.</p> </section> <section id="CD012799-sec-0136"> <h6 class="title">5.5 Participant distress about premature ejaculation</h6> <p>We found no studies using fluoxetine that evaluated participant distress about PE.</p> </section> <section id="CD012799-sec-0137"> <h6 class="title">5.6 Relationship difficulties</h6> <p>We found no studies using fluoxetine that evaluated relationship difficulties.</p> </section> <section id="CD012799-sec-0138"> <h6 class="title">5.7 Adverse events</h6> <p>We found four studies that administered fluoxetine at the following doses: 20 mg daily (<a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>), 40 mg daily (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>), and 90 mg daily (<a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>). The RR for adverse events was 9.32 (95% CI 1.88 to 46.26) with 20 mg daily, 2.29 (95% CI 0.55 to 9.49) with 40 mg daily and 1.78 (95% CI 0.76 to 4.17) with 90 mg daily (<a href="./references#CD012799-fig-0039" title="">Analysis 5.2</a>). The test for interaction was not significant (P = 0.2; I² = 37.9%). </p> </section> <section id="CD012799-sec-0139"> <h6 class="title">5.8 Intravaginal ejaculatory latency time</h6> <p>We found five studies that administered fluoxetine at the following doses: 20 mg daily (<a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>; <a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a>; <a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a>), 40 mg daily (<a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a>), and 90 mg daily (<a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>). The MD for IELT was 2.87 (95% CI 1.26 to 4.48) with 20 mg daily, –0.54 (95% CI –3.54 to 2.46) with 40 mg daily and 2.72 (95% CI 1.83 to 3.61) with 90 mg daily (<a href="./references#CD012799-fig-0040" title="">Analysis 5.3</a>). The test for interaction was not significant (P = 0.11, I² = 54.1%). </p> </section> <section id="CD012799-sec-0140"> <h6 class="title">5.9 Depression</h6> <p>We found one study that administered fluoxetine 20 mg daily (<a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a>). The RR for depression in this study was 2.00 (95% CI 0.23 to 17.34; <a href="./references#CD012799-fig-0041" title="">Analysis 5.4</a>). We could not test for subgroup differences. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012799-sec-0141" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012799-sec-0141"></div> <section id="CD012799-sec-0142"> <h3 class="title" id="CD012799-sec-0142">Summary of main results</h3> <p>We included 31 RCTs with 8254 participants and found that compared to placebo, SSRI treatment for PE probably improves perception of change with treatment, satisfaction with intercourse, perceived control over ejaculation, participant distress about PE, relationship difficulties and IELT. However, the administration of SSRIs may increase study withdrawals due to adverse events and probably increases adverse events. </p> </section> <section id="CD012799-sec-0143"> <h3 class="title" id="CD012799-sec-0143">Overall completeness and applicability of evidence</h3> <p> <ul id="CD012799-list-0027"> <li> <p>This review included 31 RCTs of 8254 participants with PE with diverse clinical characteristics that, therefore, likely reflect the population encountered in day‐to‐day clinical practice. They also included a range of SSRI drugs and dosing schedules utilized in the included trials. </p> </li> <li> <p>The review did not include any active comparators and, therefore, is unable to address how these drugs compare to other management approaches such as topical anesthetics, tramadol or α1‐adrenoreceptor antagonists, which are recommended as treatment alternatives in the recent AUA guideline (<a href="./references#CD012799-bbs2-0177" title="ShindelAW , AlthofSE , CarrierS , ChouR , McMahonCG , MulhallJP , et al. Disorders of ejaculation: an AUA/SMSNA guideline, 2020. www.auanet.org/guidelines/disorders-of-ejaculation (accessed 28 October 2020).">Shindel 2020</a>).  </p> </li> <li> <p>A specific concern in the use of SSRI for depression is the potential risk of promoting suicidal ideation, although this remains an issue of controversy (<a href="./references#CD012799-bbs2-0145" title="KhanA , KhanS , KoltsR , BrownWA . Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. American Journal of Psychiatry2003;160(4):790-2.">Khan 2003</a>; <a href="./references#CD012799-bbs2-0176" title="SharmaT , GuskiLS , FreundN , GotzschePC . Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ2016;352:i65.">Sharma 2016</a>). The reported adverse events and study withdrawals of the included studies did not provide a signal for this outcome, but we also recognize that the overall number of participants and the relatively short follow‐up of these studies limit the ability to identify infrequent outcomes that might be associated with long‐term use.     </p> </li> </ul> </p> </section> <section id="CD012799-sec-0144"> <h3 class="title" id="CD012799-sec-0144">Quality of the evidence</h3> <p>We consistently downgraded the certainty of evidence by one or two steps to moderate or low. Our confidence in the estimates of effect were primarily limited by study limitations and heterogeneity. Most studies were classified at unclear or high risk of bias for multiple domains and, therefore, the potential biases in those studies introduced a degree of uncertainty in the calculated summary estimates. </p> </section> <section id="CD012799-sec-0145"> <h3 class="title" id="CD012799-sec-0145">Potential biases in the review process</h3> <p> <ul id="CD012799-list-0028"> <li> <p>Despite a comprehensive search strategy without any publication or language restrictions, there is a possibility that we may have missed studies published in a language other than English, published in non‐indexed journals or unpublished. </p> </li> <li> <p>There were fewer than 10 studies included for most outcomes and, therefore, we were unable to generate funnel plots thus possibly underestimating the risk of publication bias. </p> </li> <li> <p>We contacted authors of each of the studies for further information, but only one responded to these requests (<a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a>), and this may be a further source of bias. </p> </li> <li> <p>One author contributing several individual studies to this review, which were all at unclear risk of selective bias (as most included studies of this review) has had six studies on men's sexual health retracted due to alleged fraud (<a href="./references#CD012799-bbs2-0162" title="Retractionwatch. Urology researcher in Iran up to six retractions, 2015. retractionwatch.com/2015/04/24/urology-researcher-in-iran-up-to-six-retractions/ (accessed 28 October 2020).">Retractionwatch 2015</a>). Since none of the included studies were involved (<a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a>; <a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a>; <a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a>; <a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a>), we included these studies in this review. However, it does underscore the issue of how important a priori trial registration is (<a href="./references#CD012799-bbs2-0165" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463.">Roberts 2015</a>). </p> </li> </ul> </p> </section> <section id="CD012799-sec-0146"> <h3 class="title" id="CD012799-sec-0146">Agreements and disagreements with other studies or reviews</h3> <p>There is a limited number of reviews that have compared SSRIs with placebo for PE. In contrast to our review, which focused on outcome of direct patient importance, they typically used IELT as a primary outcome. Also, none applied the same methodologic rigor as we applied in this review.  </p> <p> <ul id="CD012799-list-0029"> <li> <p><a href="./references#CD012799-bbs2-0123" title="CastiglioneF , AlbersenM , HedlundP , GratzkeC , SaloniaA , GiulianoF . Current pharmacological management of premature ejaculation: a systematic review and meta-analysis. European Urology2016;69(5):904-16.">Castiglione 2016</a> assessed various pharmacologic interventions for PE using IELT as the primary outcome found that SSRIs prolonged IELT compared to placebo based on the 14 included trials. </p> </li> <li> <p><a href="./references#CD012799-bbs2-0194" title="ZhangD , ChengY , WuK , MaQ , JiangJ , YanZ . Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis. BMC Urology2019;19(1):2.">Zhang 2019</a> found that paroxetine was more effective than fluoxetine and escitalopram in delaying ejaculation. The review also found that paroxetine combined with tadalafil or behavior therapy was more effective than paroxetine alone. This is consistent with <a href="./references#CD012799-bbs2-0182" title="SunY , YangL , BaoY , LiuZ , LiuL , WeiQ . Efficacy of PDE5Is and SSRIs in men with premature ejaculation: a new systematic review and five meta-analyses. World Journal of Urology2017;35(12):1817-31.">Sun 2017</a>, which reported that the pooled effects of SSRIs were superior to placebo in prolonging IELT in men with PE but found that SSRI alone was inferior to combination treatment of SSRI and phosphodiesterase‐5 inhibitors. However, there was no difference in IELT between paroxetine, tramadol, sertraline, phosphodiesterase 5 inhibitors, topical lidocaine gel, behavioral therapy or dapoxetine (<a href="./references#CD012799-bbs2-0194" title="ZhangD , ChengY , WuK , MaQ , JiangJ , YanZ . Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis. BMC Urology2019;19(1):2.">Zhang 2019</a>). These assessments were outside the scope of this review which focused on the comparison with placebo/no intervention. </p> </li> <li> <p>Again using IELT as the primary outcome, one network meta‐analysis reported that a range of SSRI agents outperformed placebo (<a href="./references#CD012799-bbs2-0143" title="JianZ , WeiX , YeD , LiH , WangK . Pharmacotherapy of premature ejaculation: a systematic review and network meta-analysis. International Urology and Nephrology2018;50(11):1939-48.">Jian 2018</a>). However, this study reported that topical anesthetics or phosphodiesterase‐5 inhibitors plus SSRIs were likely to be the most efficacious treatment strategies for PE. </p> </li> <li> <p>Another network meta‐analysis of 44 studies including a range of pharmacologic agents for PE reported that dapoxetine was likely to be the most efficacious (<a href="./references#CD012799-bbs2-0180" title="SridharanK , SivaramakrishnanG , SequeiraR , Al-KhajaKA . Pharmacological interventions for premature ejaculation: a mixed-treatment comparison network meta-analysis of randomized clinical trials. International Journal of Impotence Research2018;30(5):215-23.">Sridharan 2018</a>). Similar to this review, <a href="./references#CD012799-bbs2-0180" title="SridharanK , SivaramakrishnanG , SequeiraR , Al-KhajaKA . Pharmacological interventions for premature ejaculation: a mixed-treatment comparison network meta-analysis of randomized clinical trials. International Journal of Impotence Research2018;30(5):215-23.">Sridharan 2018</a> also found that dapoxetine, venlafaxine and fluoxetine all increased the incidence of adverse events. </p> </li> </ul> </p> <p>Other relevant document are currently available guidelines on this topic. These use varying methodology when it comes not only to the framework of moving from evidence to recommendations but also to what extent these are supported by rigorous systematic reviews. </p> <p> <ul id="CD012799-list-0030"> <li> <p>The European Association for Urology (EAU) guidelines on ED, PE, penile curvature and priapism recommend pharmacotherapy as first‐line therapy of lifelong PE (grade A) states that on‐demand dapoxetine (as the only approved pharmacologic therapy for PE) or other off‐label antidepressants such as daily SSRIs (<a href="./references#CD012799-bbs2-0134" title="HatzimouratidisK , AmarE , EardleyI , GiulianoF , HatzichristouD , MontorsiF , et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Urology2010;57(5):804-14.">Hatzimouratidis 2010</a>). This report was supported by a literature search; then "… the panel reviewed and selected the articles with the highest evidence available." The EAU did not perform its own meta‐analysis.  </p> </li> <li> <p>The International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of PE states that there is "robust evidence to support the efficacy and safety of on‐demand dosing of dapoxetine for the treatment of lifelong and acquired PE" and to "support the efficacy and safety of off‐label daily dosing of the SSRIs paroxetine sertraline, citalopram, fluoxetine" (<a href="./references#CD012799-bbs2-0118" title="AlthofSE , McMahonCG , WaldingerMD , SerefogluEC , ShindelAW , AdaikanPG , et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). Journal of Sexual Medicine2014;11(6):1392-422. [DOI: 10.1111/jsm.12504]">Althof 2014</a>). These recommendations were supported by a comprehensive literature search and a consensus‐based process.  </p> </li> <li> <p>Guidelines of the AUA are the most recent; they are also the most methodologically rigorous supported by a systematic review conducted by the Pacific Northwest Evidence‐based Practice Centre that was up‐to‐date up to March 2019 (<a href="./references#CD012799-bbs2-0177" title="ShindelAW , AlthofSE , CarrierS , ChouR , McMahonCG , MulhallJP , et al. Disorders of ejaculation: an AUA/SMSNA guideline, 2020. www.auanet.org/guidelines/disorders-of-ejaculation (accessed 28 October 2020).">Shindel 2020</a>). This document makes a strong recommendation that "clinicians should recommend daily SSRIs; on‐demand clomipramine or dapoxetine (where available) … as first‐line pharmacotherapies in the treatment of PE." However, the guideline group did not conduct their meta‐analysis or own update meta‐analyses from previously published reviews systematic reviews. </p> </li> </ul> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012799-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012799-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies." data-id="CD012799-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD012799-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.1 Participant perception of change with treatment." data-id="CD012799-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.1 Participant perception of change with treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.2 Participant satisfaction with intercourse." data-id="CD012799-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.2 Participant satisfaction with intercourse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.3 Study withdrawal due to adverse events." data-id="CD012799-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 SSRI versus placebo, outcome: 1.3 Study withdrawal due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus placebo, Outcome 1: Participant perception of change with treatment" data-id="CD012799-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus placebo, Outcome 1: Participant perception of change with treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus placebo, Outcome 2: Participant satisfaction with intercourse" data-id="CD012799-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus placebo, Outcome 2: Participant satisfaction with intercourse</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus placebo, Outcome 3: Study withdrawal due to adverse events" data-id="CD012799-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus placebo, Outcome 3: Study withdrawal due to adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus placebo, Outcome 4: Perceived control over ejaculation" data-id="CD012799-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus placebo, Outcome 4: Perceived control over ejaculation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus placebo, Outcome 5: Participant distress about PE" data-id="CD012799-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus placebo, Outcome 5: Participant distress about PE</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus placebo, Outcome 6: Relationship difficulties" data-id="CD012799-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus placebo, Outcome 6: Relationship difficulties</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus placebo, Outcome 7: Adverse events" data-id="CD012799-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus placebo, Outcome 7: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus placebo, Outcome 8: Intravaginal ejaculatory latency time" data-id="CD012799-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus placebo, Outcome 8: Intravaginal ejaculatory latency time</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: SSRI versus placebo, Outcome 9: Depression" data-id="CD012799-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: SSRI versus placebo, Outcome 9: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 1: Participant perception of change with treatment" data-id="CD012799-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 1: Participant perception of change with treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 2: Participant satisfaction with intercourse" data-id="CD012799-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 2: Participant satisfaction with intercourse </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 3: Study withdrawal due to adverse events" data-id="CD012799-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 3: Study withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 4: Perceived control over ejaculation" data-id="CD012799-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 4: Perceived control over ejaculation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 5: Participant distress about PE" data-id="CD012799-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 5: Participant distress about PE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 6: Relationship difficulties" data-id="CD012799-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 6: Relationship difficulties </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 7: Adverse events" data-id="CD012799-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 7: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 8: Intravaginal ejaculatory latency time" data-id="CD012799-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 8: Intravaginal ejaculatory latency time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 9: Depression" data-id="CD012799-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: long‐acting versus short‐acting SSRI, Outcome 9: Depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 1: Participant perception of change with treatment" data-id="CD012799-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 1: Participant perception of change with treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 2: Study withdrawal due to adverse events" data-id="CD012799-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 2: Study withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 3: Adverse events" data-id="CD012799-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 3: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 4: Intravaginal ejaculatory latency time" data-id="CD012799-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 4: Intravaginal ejaculatory latency time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 5: Depression" data-id="CD012799-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis: comparison of long‐acting agents, Outcome 5: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 1: Participant perception of change with treatment" data-id="CD012799-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 1: Participant perception of change with treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 2: Participant satisfaction with intercourse" data-id="CD012799-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 2: Participant satisfaction with intercourse </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 3: Study withdrawal due to adverse events" data-id="CD012799-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 3: Study withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 4: Perceived control over ejaculation" data-id="CD012799-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 4: Perceived control over ejaculation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 5: Participant distress about PE" data-id="CD012799-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 5: Participant distress about PE </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 6: Relationship difficulties" data-id="CD012799-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 6: Relationship difficulties </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 7: Adverse events" data-id="CD012799-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 7: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 8: Intravaginal ejaculatory latency time" data-id="CD012799-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis: different doses of dapoxetine, Outcome 8: Intravaginal ejaculatory latency time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis: different doses of fluoxetine, Outcome 1: Study withdrawal due to adverse events" data-id="CD012799-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis: different doses of fluoxetine, Outcome 1: Study withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis: different doses of fluoxetine, Outcome 2: Adverse events" data-id="CD012799-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis: different doses of fluoxetine, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis: different doses of fluoxetine, Outcome 3: Intravaginal ejaculatory latency time" data-id="CD012799-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis: different doses of fluoxetine, Outcome 3: Intravaginal ejaculatory latency time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012799-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/urn:x-wiley:14651858:media:CD012799:CD012799-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis: different doses of fluoxetine, Outcome 4: Depression" data-id="CD012799-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_t/tCD012799-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis: different doses of fluoxetine, Outcome 4: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/media/CDSR/CD012799/image_n/nCD012799-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012799-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">SSRI compared to placebo for premature ejaculation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>SSRI compared to placebo for premature ejaculation in adult men</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult men with premature ejaculation<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> SSRI<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with SSRI</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant perception of change with treatment</b><br/>assessed with: Clinical Global Impression of Change questionnaire (event is good as it represents improvement in symptoms) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3260<br/>(6 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.92</b><br/>(1.66 to 2.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in perceived improvement compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 more per 1000<br/>(145 more to 270 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant satisfaction with intercourse</b><br/>assessed with: Premature Ejaculation Profile questionnaire (event is good as it represents increased satisfaction) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4273<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.63</b><br/>(1.42 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in improved satisfaction with intercourse compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 more per 1000<br/>(117 more to 242 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study withdrawal due to adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>7367<br/>(20 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.80</b><br/>(2.61 to 5.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI may result in more withdrawals due to adverse events compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 more per 1000<br/>(17 more to 49 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Perceived control over ejaculation</b><br/>assessed with: Premature Ejaculation Profile questionnaire (event is good as it represents increased control over ejaculation) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4273<br/>(3 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.29</b><br/>(1.72 to 3.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in improved perceived control over ejaculation compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170 more per 1000<br/>(95 more to 270 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant distress about PE</b><br/>assessed with: Premature Ejaculation Profile questionnaire (event is good as it represents less distress) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>652<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.54</b><br/>(1.26 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in increased numbers of men not distressed about PE compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>353 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 more per 1000<br/>(92 more to 311 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4624<br/>(17 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.71</b><br/>(1.48 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SSRI probably results in increased adverse events compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 more per 1000<br/>(117 more to 241 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IELT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5872<br/>(20 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean IELT was 1.41 minutes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.09 minutes</b> higher<br/>(1.94 higher to 4.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SSRI probably results in extended IELT compared to placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IELT:</b> intravaginal ejaculatory latency time; <b>MD:</b> mean difference; <b>PE:</b> premature ejaculate; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SSRI:</b> selective serotonin reuptake inhibitor. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: most studies had an unclear or high risk of selection, performance and detection bias.<br/><sup>b</sup>Not downgraded for high I² statistic since observed inconsistency did not appear clinically relevant.<br/><sup>c</sup>Downgraded one level due to serious concerns regarding attrition bias.<br/><sup>d</sup>Downgraded one level for serious inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">SSRI compared to placebo for premature ejaculation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012799-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of the interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) (route, frequency, total dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator(s) (route, frequency, total dose/day)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily for first 1 week and 40 mg daily for remaining 5 weeks after breakfast </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: duloxetine 20 mg daily for 1 week followed by 40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: citalopram 20 mg daily up to 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily up to 3 tablets</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg on‐demand</p> <p>I2: dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> <p>C2: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: citalopram 20 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo on‐demand</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg on‐demand + lubricating jelly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo on‐demand + lubricating jelly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: tramadol 50 mg</p> <p>I2: paroxetine 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg</p> <p>I2: paroxetine 20 mg 2–3 hours before intercourse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 40 mg daily for 1 week then 80 mg for 3 weeks</p> <p>I2: sertraline 100 mg for 1 week then 200 mg for 3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> <p>C2: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 90 mg daily</p> <p>I2: fluoxetine 90 mg daily + tadalafil 20 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> <p>C2: placebo + tadalafil 20 mg on‐demand</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg</p> <p>I2: paroxetine as needed 3–4 hours before planned sexual intercourse</p> <p>I3: paroxetine 10 mg for 3 weeks then 20 mg paroxetine as needed for 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily for 3 weeks then placebo daily for 4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg daily</p> <p>I2: dapoxetine 60 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> <p>C2: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg on‐demand, from week 4 up to 60 mg if tolerated + PDE5 inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo on‐demand + PDE5 inhibitor</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg daily that could be titrated up to 200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg at night that could be titrated up to 100 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg on‐demand</p> <p>I2: dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo on‐demand 1–3 hours before anticipated sexual activity</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 60 mg daily</p> <p>I2: paroxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: citalopram 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: escitalopram 10 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: dapoxetine 30 mg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo twice daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: citalopram 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: sertraline 50 mg nightly for 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily for 2 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg daily for 1 week and then 40 mg daily from week 2–6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily</p> <p>I2: fluvoxamine 100 mg daily</p> <p>I3: paroxetine 20 mg daily</p> <p>I4: sertraline 50 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: placebo daily</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>C: comparator; I: intervention; PDE5: phosphodiesterase‐5.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of the interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012799-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Duration of intervention </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Age in years (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Baseline IELT in minutes (mean)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants with primary/secondary PE</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0001" title="Ahn Ty, ParkH , Choi Eh, ChooMS , ParkT . Fluoxetine as a treatment for premature ejaculation: a double-blind, randomized, placebo-controlled study. Korean Journal of Urology1996;37(8):926-31. ">Ahn 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: fluoxetine 20 mg daily for first 1 week and 40 mg daily for remaining 5 weeks after breakfast </p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.8 (range 34–48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (range 0.17–2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.8 (range 34–48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (range 0.17–2.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0002" title="AthanasiosZ , PolyanthiP , GeorgeK . The efficacy of duloxetine in the treatment of premature ejaculation. International Urology and Nephrology2007;39(1):115-8. ">Athanasios 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: duloxetine 20 mg daily for 1 week followed by 40 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Greece</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.35 (SD 8.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (SD 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.65 (SD 7.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (SD 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0003" title="AtmacaM , KulogluM , TezcanE , SemerciozA . The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. International Journal of Impotence Research2002;14(6):502-5. ">Atmaca 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: citalopram 20 mg daily up to 60 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 24–46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 (SD 0.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 24–46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (SD 0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0004" title="BiriH , IsenK , SinikZ , OnaranM , KupeliB , BozkirliI . Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study. International Urology and Nephrology1998;30(5):611-5. ">Biri 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1995–1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (SD 0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (SD 0.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0005" title="BuvatJ , TesfayeF , RothmanM , RivasDA , GiulianoF . Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Urology2009;55(4):957-67. ">Buvat 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: dapoxetine 30 mg on‐demand</p> <p>I2: dapoxetine 60 mg on‐demand</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2004–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.6 (SD 9.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (SD 0.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.5 (SD 9.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (SD 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.1 (SD 9.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (SD 0.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0006" title="FarniaV , RaisiF , MohseniMG , AtharikiaD , GhafuriZ . On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Iranica2009;47:353-5. ">Farnia 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: citalopram 20 mg on‐demand</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2006–2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.28 (SD 6.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.11 (SD 0.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.76 (SD 5.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (SD 0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012799-bbs2-0007" title="GameelT , TawfeekA , Abou FarhaM , BastawesyM , BendaryM , GamasyA . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomized placebo-controlled clinical trial. Journal of Sexual Medicine2018;15(2):S54. GameelTA , TawfikAM , Abou-FarhaMO , BastawisyMG , El-BendaryMA , El-Gamasy AelN . On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab Journal of Urology2013;11(4):392-7. GameelTA , TawfikAM , SolimanMG , El-BendaryMA , Abo-ElenenM , TawfikTI , et al. On demand use of tramadol, sildenafil, paroxetine or local anesthetics for management of premature ejaculation, a randomized placebo controlled clinical trial. European Urology, Supplements2013;12(1):e214. ">Gameel 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: paroxetine 20 mg on‐demand + lubricating jelly</p> <p>C1: placebo on‐demand + lubricating jelly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16 (SD 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0008" title="GongZY , TangTL , CuiS , WangJZ , DengXZ . Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue [National Journal of Andrology]2011;17(10):923-5. ">Gong 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: paroxetine 20 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>likely outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.8 (SD 5.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (SD 0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2 (SD 6.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (SD 0.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0009" title="Hamidi-MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. Journal of Reproduction and Infertility2016;19(1):10-5. Hamidi MadaniA , MotieeR , MokhtariG , NassehH , EsmaeiliS , KazemnezhadE . The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation. European Urology, Supplements2016;15(3):e1001. ">Hamidi Madani 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: tramadol 50 mg</p> <p>I2: paroxetine 20 mg</p> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0010" title="KaraH , AydinS , YucelM , AgargunMY , OdabasO , YilmazY . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. Journal of Urology1996;156(5):1631-2. ">Kara 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: fluoxetine 20 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 15–50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42 (SD 0.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 15–50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (SD 0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0011" title="KaufmanJM , RosenRC , MudumbiRV , TesfayeF , HashmonayR , RivasD . Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU International2009;103(5):651-8. ">Kaufman 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: dapoxetine 60 mg on‐demand</p> <p>C1: placebo on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA and Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.8 (SD 9.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.98 (SD 9.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0012" title="KhelaiaA , ManagadzeL . Does still is a place for paroxetine in the era of dapoxetine. Andrology2014;2:100. KhelaiaA . Does still is a place for paroxetine in the era of dapoxetine. Journal of Sexual Medicine2015;12:214. KhelaiaAV , BochorishviliGG , ManagadzeLG . 697 Assessment of paroxetine in the treatment of premature ejaculation and dosage optimization. European Urology Supplements2012;11(1):e697-e697a. ">Khelaia 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: paroxetine 20 mg</p> <p>I2: paroxetine 20 mg 2–3 hours before intercourse</p> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Georgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.7 (range 19–39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.7 (range 19–39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.7 (range 19–39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0013" title="KimSC , SeoKK . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. Journal of Urology1998;159(2):425-7. ">Kim 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: fluoxetine 40 mg daily for 1 week then 80 mg for 3 weeks</p> <p>I2: sertraline 100 mg for 1 week then 200 mg for 3 weeks</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (range 30–60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (SD 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (range 30–60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (SD 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (range 30–60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (SD 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012799-bbs2-0014" title="MattosRM , Marmo LuconA , SrougiM . Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urologia Internationalis2008;80(2):162-5. ">Mattos 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>I1: fluoxetine 90 mg daily</p> <p>I2: fluoxetine 90 mg daily + tadalafil 20 mg on‐demand</p> <p>C1: placebo daily</p> <p>C2: placebo + tadalafil 20 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (SD 8.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (SD 0.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42.81 (SD 7.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (SD 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.93 (SD 9.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (SD 0.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2 (SD 11.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (SD 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0015" title="McMahonCG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. Journal of Urology1998;159(6):1935-8. ">McMahon 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (range 19–70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (range 19–70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD012799-bbs2-0016" title="McMahonCG , ToumaK . Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. Journal of Urology1999;161(6):1826-30. ">McMahon 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study 1: </b> </p> <p>I1: paroxetine 20 mg</p> <p>C1: paroxetine as needed 3–4 hours before planned sexual intercourse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>17 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study 2: </b> </p> <p>I2: paroxetine 10 mg for 3 weeks then 20 mg paroxetine as needed for 4 weeks</p> <p>C2: placebo daily for 3 weeks then placebo daily for 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0017" title="GiulianoF , LevineSB , BuvatJ , RosenRC , KaufmanJM , TesfayeF , et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine (DPX) for the treatment of premature ejaculation (PE): results from 2 phase III trials. European Urology Supplements2008;7(3):187. McMahonC , KimSW , ParkNC , ChangCP , RivasD , TesfayeF , et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Journal of Sexual Medicine2010;7(1 Pt 1):256-68. McMahonC , ParkNC , ZhaoY , RivasD , RothmanM . Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. International Journal of Urology2010;17:A195. ">McMahon 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: dapoxetine 30 mg on‐demand</p> <p>I2: dapoxetine 60 mg on‐demand</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2005–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Multicenter in Asia/Pacific</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2 (SD 10.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (42.2%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.0 (SD 10.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (42.2%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.6 (SD 9.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (45.9%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0018" title="McMahonCG , GiulianoF , DeanJ , HellstromWJ , BullS , TesfayeF , et al. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. Journal of Sexual Medicine2013;10(9):2312-25. ">McMahon 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: dapoxetine 30 mg on‐demand, from week 4 up to 60 mg if tolerated + PDE5 inhibitor taken 1–3 hours prior to sexual intercourse </p> <p>C1: placebo daily + PDE5 inhibitor taken 1–3 hours prior to intercourse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010–2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.5 (SD 11.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 (42.2%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.9 (SD 11.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 (45.9%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0019" title="MendelsJ , CameraA , SikesC . Sertraline treatment for premature ejaculation. Journal of Clinical Psychopharmacology1995;15(5):341-6. ">Mendels 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg daily that could be titrated up to 200 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (SD 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (SD 1.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0020" title="NaKI , KimJJ . Sertraline treatment in premature ejaculation: a double blind, randomized, placebo-controlled study. Journal of Korean Andrological Society1996;14(2):101-4. ">Na 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg at night that could be titrated up to 100 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0021" title="NovarettiJP , PompeoAC , ArapS . Selective serotonin uptake inhibitor in the treatment of premature ejaculation. Brazilian Journal of Urology2002;28:116-22. ">Novaretti 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: fluoxetine 20 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1998–2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.4 (SD 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.01 (SD 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.4 (SD 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (SD 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0022" title="PryorJL , AlthofSE , SteidleC , MiloslavskyM , KellS . Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Journal of Urology2005;173(4):S201. PryorJL , AlthofSE , SteidleC , RosenRC , HellstromWJ , ShabsighR , et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet2006;368(9539):929-37. ">Pryor 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: dapoxetine 30 mg on‐demand 1–3 hours before anticipated sexual activity</p> <p>I2: dapoxetine 60 mg on‐demand 1–3 hours before anticipated sexual activity</p> <p>C1: placebo on‐demand 1–3 hours before anticipated sexual activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2003–2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.3 (SD 9.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (SD 0.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>563/227</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.9 (SD 9.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (SD 0.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571/234</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.3 (SD 9.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (SD 0.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560/248</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012799-bbs2-0023" title="SafarinejadMR . Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clinical Neuropharmacology2006;29(5):243-52. ">Safarinejad 2006b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>I1: dapoxetine 60 mg daily</p> <p>I2: paroxetine 20 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2003–2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.4 (range 20–50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (61.5%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.6 (range 21–49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (60.0%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.3 (range 21–50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (44.0%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0024" title="SafarinejadMR , HosseiniSY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. International Journal of Impotence Research2006;18(2):164-9. ">Safarinejad 2006c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: citalopram 30 mg</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (21–49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (21–49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0025" title="SafarinejadMR . Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Journal of Clinical Psychopharmacology2007;27(5):444-50. ">Safarinejad 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: escitalopram 10 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2003–2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.5 (range 21–44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (70%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.3 (range 19–46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (69.8%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0026" title="SafarinejadMR . Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology2008;33(6):1259-65. ">Safarinejad 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: dapoxetine 30 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004–2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.7 (range 21–54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (37.7%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.3 (range 19–56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (40.6%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0027" title="ShangXJ , GengQ , ZhangK , XiaXY , ShaoY , HuangYF . Efficacy of citalopram on premature ejaculation: a clinical observation. Zhonghua Nan Ke Xue [National Journal of Andrology]2012;18(12):1097-100. ">Shang 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: citalopram 20 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2011–2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.1 (SD 2.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (SD 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.8 (SD 2.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (SD 0.17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0028" title="TuncelA , AslanY , BaşarMM , AtanA . Efficacy of clomipramine, sertraline and terazosin treatments in premature ejaculation. Turkish Journal of Medical Sciences2008;38(1):59-64. ">Tuncel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: sertraline 50 mg nightly for 2 months</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.9 (median) (SD 6.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.9 (median) (SD 9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0029" title="WaldingerMD , HengeveldMW , ZwindermanAH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry1994;151(9):1377-9. ">Waldinger 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: paroxetine 20 mg daily for 1 week and then 40 mg daily from week 2–6</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (range 27–48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/8 (87.5%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (range 30–47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/9 (77.7%)/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD012799-bbs2-0030" title="WaldingerMD , HengeveldMW , ZwindermanAH , OlivierB . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology1998;18(4):274-81. ">Waldinger 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>I1: fluoxetine 20 mg daily</p> <p>I2: fluvoxamine 100 mg daily</p> <p>I3: paroxetine 20 mg daily</p> <p>I4: sertraline 50 mg daily</p> <p>C1: placebo daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>The Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (SD 7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (SD 10.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (SD 8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (SD 9.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (SD 4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (SD 0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012799-bbs2-0031" title="YilmazU , TatlisenA , TuranH , ArmanF , EkmekciogluO . The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. Journal of Urology1999;161(1):107-11. ">Yilmaz 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I1: fluoxetine 20 mg daily</p> <p>C1: placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1997–1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Academic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.5 (range 22–56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (SD 1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.3 (range 24–58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1 (SD 1.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA/NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>C: comparator; I: intervention; IELT: intravaginal ejaculatory latency time; NA: not available; NR: not reported; PDE5: phosphodiesterase‐5; PE: premature ejaculation; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/full#CD012799-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012799-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SSRI versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Participant perception of change with treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.66, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Participant satisfaction with intercourse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.42, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Study withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [2.61, 5.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Perceived control over ejaculation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.72, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Participant distress about PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.26, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Relationship difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.07, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.48, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Intravaginal ejaculatory latency time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [1.94, 4.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.23, 17.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">SSRI versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012799-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: long‐acting versus short‐acting SSRI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Participant perception of change with treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.66, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Long‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.48 [2.21, 32.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Short‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.66, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Participant satisfaction with intercourse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.42, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Short‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.42, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Study withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.71 [2.56, 5.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Long‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.92, 4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Short‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.33 [2.60, 7.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Perceived control over ejaculation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.72, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Short‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.72, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Participant distress about PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.26, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Short‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.26, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Relationship difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.07, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Short‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.07, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.48, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Long‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.37, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Short‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.42, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Intravaginal ejaculatory latency time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [1.57, 3.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Long‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [1.62, 5.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Short‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.27, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.23, 17.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Long‐acting SSRI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.23, 17.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: long‐acting versus short‐acting SSRI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012799-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis: comparison of long‐acting agents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Participant perception of change with treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.48 [2.21, 32.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [1.32, 61.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.00 [1.21, 52.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Study withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.92, 4.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 70.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Dapoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.64 [0.99, 58.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 Escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.37, 10.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.5 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [0.34, 19.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.6 Fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.09, 25.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.7 Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.35, 8.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.8 Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.05, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [1.44, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.51, 17.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Clomipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.40 [1.06, 18.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Dapoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.34, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.37, 24.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.5 Escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.69, 4.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.6 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.29, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.7 Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.91, 6.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.8 Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.74, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Intravaginal ejaculatory latency time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [1.62, 5.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Citalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.85 [3.14, 6.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Duloxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.80, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.3 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [1.52, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.4 Fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [‐0.35, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.5 Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.51 [0.33, 12.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.6 Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [1.54, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.23, 17.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.23, 17.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis: comparison of long‐acting agents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012799-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis: different doses of dapoxetine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Participant perception of change with treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.66, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Dapoxetine 30 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.37, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Dapoxetine 30 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [1.33, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Dapoxetine 60 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.23, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 Dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.58, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Participant satisfaction with intercourse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.37, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Dapoxetine 30 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.08, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Dapoxetine 30 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.33, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Dapoxetine 60 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.07, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.4 Dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.32, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Study withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.54 [2.89, 7.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Dapoxetine 30 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.37, 25.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Dapoxetine 30 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [1.06, 5.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Dapoxetine 60 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.76 [2.10, 36.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 Dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.51 [3.64, 11.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Perceived control over ejaculation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.72, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Dapoxetine 30 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.26, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Dapoxetine 30 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [2.72, 5.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Dapoxetine 60 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.26, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.4 Dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.65, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Participant distress about PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.26, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.26, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Relationship difficulties <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.07, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.07, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.46, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Dapoxetine 30 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.30, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Dapoxetine 30 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.20, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.3 Dapoxetine 60 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [2.03, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.4 Dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.23, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Intravaginal ejaculatory latency time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.20, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Dapoxetine 30 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.27, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 Dapoxetine 30 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.86, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.3 Dapoxetine 60 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.98, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.4 Dapoxetine 60 mg on‐demand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.09, 1.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis: different doses of dapoxetine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012799-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis: different doses of fluoxetine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Study withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.26, 16.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.26, 16.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.29, 4.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.32 [1.88, 46.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Fluoxetine 40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [0.55, 9.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Fluoxetine 90 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.76, 4.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Intravaginal ejaculatory latency time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [1.52, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [1.26, 4.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Fluoxetine 40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐3.57, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 Fluoxetine 90 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.72 [1.83, 3.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.23, 17.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Fluoxetine 20 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.23, 17.34]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis: different doses of fluoxetine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012799.pub2/references#CD012799-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012799.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012799-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012799-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012799-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012799-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012799-note-0013">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD012799-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012799-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012799-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012799-note-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012799-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012799-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012799\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012799\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012799\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012799\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012799\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012799.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012799.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012799.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012799.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012799.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727629459"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012799.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727629463"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012799.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb0b9b925936d',t:'MTc0MDcyNzYyOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 